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Proteins constitute the majority of nature’s worker biomolecules. Designed for 11 
specific functions, complex tertiary structures make proteins ideal candidates for analyzing 12 
natural systems and creating novel biological tools. Due to both large size and the need for 13 
proper folding, de novo synthesis of proteins has been quite a challenge, leading scientists to 14 
focus on modifying protein templates already provided by nature. Recently developed 15 
methods for protein modification fall into two broad categories: those that can modify the 16 
natural protein template directly and those that require genetic manipulation of the amino 17 
acid sequence prior to modification. The goal of this review is to provide not only a window 18 
through which to view the many opportunities created by novel protein modification 19 
techniques, but also to act as an initial guide to help scientists find direction and form ideas 20 
in an ever-growing field. In addition to the highlighting methods reported in the past five 21 
years, we aim to provide a broader sense of the goals and outcomes of protein modification 22 
and bioconjugation in general. While the main body of the paper comprises reactions directly 23 
 2 
involving proteins as a starting material, some further functionalization strategies as well as 24 
biological applications are also acknowledged. The discussion concludes by speculating what 25 
trends and discoveries will most likely come next in the field. 26 
 27 
[H1] Introduction 28 
Over time, proteins have become the most valuable biomolecules among the vast variety 29 
of cellular components. Due to their multifaceted nature, performing many roles both within and 30 
outside of the cell cycle, amino acid-based (AA-based) protein modification can lead to a myriad 31 
of diverse applications.1,2 This is particularly apparent in the field of bioconjugates where 32 
therapeutic potential in the treatment of cancer and other medical problems has led to them 33 
infiltrating the pharmaceutical market (in addition to an already established presence in smaller 34 
markets such as biomaterials, textile manufacturing, and food processing). With huge commercial 35 
value resulting from such medical promise, it is not surprising that the toolbox available to 36 
chemists is ever-expanding. 3 Enhanced bioavailability, fluorescent tracking, post- translational 37 
modification insertions, and targeted delivery are just a few of the numerous possible applications 38 
of protein conjugates.1,4 In order for these powerful applications to be realized, however, the 39 
protein modification must avoid interfering with protein function. Arguably, the ability to retain 40 
protein function is primarily affected by the site and size of the protein modification. Site-selective 41 
methods that result in homogeneous products are thus in demand because they maximize the 42 
chance of success in the desired application. 43 
Starting from classical methods that are unable to deliver site-specificity, chemical 44 
biologists have been able to improve protein modification procedures and identify routes that 45 
circumvent the inherent obstacles of bioconjugation (Figure 1).5 One of the most challenging 46 
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criteria is the need for modifications to occur under mild reaction conditions, in an aqueous 47 
environment, and in the presence of multiple unprotected, chemical entities that can promote cross-48 
reactions. Moreover, promoting such reactions under natural biological conditions  while also 49 
maintaining structural and functional integrity adds an extra level of difficulty. Nevertheless, 50 
different methods have been developed that take advantage of reactive, endogenous AA 51 
sidechains.. The nucleophilicity, solvent accessibility, and relative abundance of lysine (Lys) and 52 
cysteine (Cys) residues have encouraged scientists to target these sidechains using maleimides, N-53 
hydroxysuccinimide (NHS) esters, and a-halocarbonyls as electrophiles for modification.6,7 54 
Michael addition, activated ester amidation, and reductive amination have become particularly 55 
popular (Figure 1).8 Each method presents particular advantages and disadvantages, but common 56 
motivations for the continued search for optimized protein modification methods centre on 57 
improving reaction rate and product homogeneity.  58 
Given that the available chemical functional groups are naturally limited to the canonical 59 
AAs, different strategies have been pursued to increase selectivity and improve kinetics.9 To do 60 
so, researchers have employed creative solutions that take advantage of strategies within the realm 61 
of nature (for example, enzymatic tags/recognition sites and acknowledgement of the various 62 
microenvironments within a protein’s structure), genetic engineering for the introduction of natural 63 
or abiotic functional groups (e.g. genetic sequence insertions and subsequent chemical reactions), 64 
or even previously unexplored chemistry or reaction optimizations (e.g. controlled reaction 65 
conditions or metal-catalyzed/directed reactions) (Figure 1).1,2,5,7,8,10,11 Among the most successful 66 
methods to achieve homogenous products, genetic engineering to incorporate a new amino acid 67 
(either canonical or non-canonical) within the structure of a protein followed by modification is 68 
currently the method of choice.9 Direct native protein modification is arguably the ideal, however,  69 
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(avoiding the need for any prior protein modification), and seems to be a promising emerging 70 
strategy with many more examples being described. 12 This review focuses on appraising 71 
modification methodologies from the last five years as well as novel examples of downstream 72 
functionalization of these modifications and therapeutic biological applications present in this 73 
ever-growing field of site-selective protein modification.  74 
 75 
[H1] Direct modification of native proteins 76 
With only a select number of reactive groups represented and often repeated throughout 77 
the protein sequence, modification of endogenous AAs has been difficult to accomplish with a 78 
high level of selectivity. Although challenging, the potential for the higher yields available from a 79 
single-step process has inspired efforts to develop such methods. Difficulties with conventional 80 
strategies for modifying native protein sequences result from the lack of reaction site-specificity 81 
(heterogeneous products result from repeated functionalities being modified because the methods 82 
are  site-selective rather than site-specific).1 Site-specificity can avoid the modification of reactive 83 
residues that are critical to protein function (for example, catalytic Cys residues). However, 84 
functionalization of less reactive sidechains often requires harsh reaction conditions that can be 85 
detrimental to protein activity.7 Thus, more creative methods are required, and the last five years 86 
of research in this area have highlighted two general strategies. The first relies on targeting unique 87 
and accessible N-/C-terminal chemical environments present in single-chain proteins.17 The 88 
second focuses instead on protein tertiary structures that create more reactive microenvironments 89 
that enable selective modification (for example, ligand- and metal-binding sites, hyperreactive 90 
sidechains, and disulfide bonds).18,19 91 
 92 
[H2] N-/C-terminus Modification 93 
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Terminus modifications have the potential to be more generally applicable —most protein 94 
termini are accessible and have chemical environments distinct from the remainder of the protein.  95 
Several recent discoveries have been made that improve method versatility and terminal AA 96 
tolerance while addressing past problems.17 For C-terminal modifications, targeting relies on the 97 
difference in oxidation potential between terminal carboxylic acids and  in-chain glutamic acid 98 
(Glu)/Asp residues. MacMillan and coworkers have reported a method based on visible-light-99 
mediated single-electron transfer (SET) to perform decarboxylative alkylation at C-terminal 100 
residues (3 equiv. photocatalyst, 10 equiv. Michael acceptor, 8 h, r.t., pH 3.5, 41–49% conversion, 101 
Figure 2i).16 Unlike prior amide coupling and esterification strategies, this SET reaction favors the 102 
C-terminus over carboxylic acid moieties in Glu and Asp residues.20–22 Such selectivity originates 103 
from increased stability of the C-terminal carbon-centered radical.16 The aforementioned 104 
conditions allow for the selective alkylation of human insulin at the A chain C-terminus. However, 105 
using alternate decarboxylative conditions, originally studied for targeting tryptophan residues at 106 
the peptide level, selective modification of the B chain C-terminus was observed (0.5-1 equiv. 107 
photocatalyst, 10-30 equiv. Michael acceptor, 10 equiv. K2HPO4, 2.5-3 h, DMF, Merck 108 
Photoreactor (450 nm), 15-38% conversion).23 Though the precise reasons for this selectivity 109 
remain as yet undetermined, the divergence in these C-terminal modification products showcases 110 
the number of factors at play when performing protein conjugation.  111 
When considering N-terminal modification, the first point to consider is that the N-terminal 112 
amine has pKa ~ 8 while that of an in chain Lys’s e-amine has pKa ~ 10. Thus, not only will the N-113 
terminus be charged at physiological pH, encouraging solvent accessibility, but also in slightly 114 
basic environments, the N-terminal amine will be deprotonated and more nucleophilic than those 115 
in Lys residues.24,25 Although the N-terminal amine pKa is similar to that of Cys (pKa ~ 8), Cys 116 
 6 
residues are lower in abundance and may not be as accessible as the N-terminus. Thus, Cys-117 
modification can be avoided by using protection steps or by careful, amine-reactive reagent 118 
selection.25,26 Therefore, targeting the N-terminus in a single chain protein can lead to site-specific 119 
modification. Even with such promise, the earliest reported methods targeting the N-terminus 120 
required high concentrations of modifying reagents and long reaction times.27,28 Numerous 121 
methods that address this, involving one step, low reagent concentrations, and reasonable reaction 122 
times have been reported: oxidative coupling with o-aminophenols (5 equiv. o-aminophenol, 250 123 
equiv. oxidant, 30 min, room temperature (r.t.), pH 7.5, Figure 2ii), addition of 2-124 
pyridinecarboxaldehydes (2-PCA, 400 equiv., 16 h, 37 ºC, pH 7.5, 33-95% conversion, Figure 125 
2iii), and reductive alkylation with aldehydes (2 equiv. aldehyde, 5 equiv. reductant, 6-48 h, r.t., 126 
pH 6.1, 30-70% conversion, Figure 2iv).24–26 While some N-terminal residue types show higher 127 
conversion values than others, only a few are found to be incompatible (for example, an N-terminal 128 
Cys leads to reductive alkylation).24,25 Such versatility can be even further extended by enzyme-129 
mediated modification at the N-terminus. Butelase 1 has been reported as an asparagine/aspartic 130 
acid (Asn/Asp) specific ligase to efficiently conjugate thiodepsipeptide substrates to N-terminal 131 
residues (0.001 equiv. butelase 1, 5 equiv. substrate, 2.5 h, 42 ºC, pH 6.5, 70-82% conversion, 132 
Figure 2v). Butelase 1 has a high substrate tolerance, and can successfully perform conjugation 133 
with any N-terminal AA other than proline. Reaction tends to be favouredby the presence of a 134 
hydrophobic residue in the second position.29 Having several conjugation strategies available 135 
allows navigation of the complex combinations of disadvantages and advantages in order to choose 136 
the optimal method for a diverse range of proteins and applications. 137 
While some of the aforementioned methods cannot modify proteins with certain terminal 138 
residues, the methods complement each other such that there exists at least one possible method 139 
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for every terminal residue type. Further advantages and limitations stem from specific reagents or 140 
conditions used. With o-aminophenol oxidative coupling, double modification can be seen at basic 141 
pH either due to Lys modification or dimerization.26 In the case of 2-PCA, after 12 h at 37 ºC, 20-142 
30% of the modified protein is lost.25 For the method relying on butelase 1, the short half-life of 143 
the thiodepsipeptide reagents must be acknowledged and reaction conditions adjusted.29 These 144 
limitations highlight why method diversity is needed: to allow for the choice of a modification 145 
method with limitations that will not affect the conjugate application. Such diversity also applies 146 
to the various advantages of methods: the use of reductive alkylation maintains the charge on the 147 
N-terminal amine which may be necessary for protein function, and the use of 2-PCA or o-148 
aminophenol can facilitate multiple, site-specific modifications.24–26 Optimization of older 149 
methods has also led to the progression of N-/C-terminal modification strategies. As an example, 150 
Rapoport’s Salt (RS) for oxidation at the N-terminus shows an expanded tolerance for different N-151 
terminal residues in higher pH environments (~ pH 8.5).30 The important advantages to incorporate 152 
and limitations to avoid are depend on the application of interest. However, the structure and 153 
makeup of the protein, the presence of post translational modifications (PTMs), or the need for the 154 
termini to be available for protein function,  mean that other protein modification strategies (those 155 
that target in-chain sites) are also in high demand.17,31  156 
 157 
[H2] In-chain Residue Modification 158 
 159 
Protein modification at in-chain AAs is critical for certain biological applications (e.g. 160 
profiling inhibition and modulation of enzymatic active sites).32 Careful selection of reaction type, 161 
conditions, and reagents, have enabled such modifications have been achieved using endogenous 162 
AAs.7 One such strategy is the selective targeting of Trp residues (200–300 equiv. sodium 163 
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trifluoromethanesulfinate, 25 equiv. tert-butyl hydroperoxide, 25 equiv. methionine (Met), 5–10 164 
min, 0 ºC, pH 6, 65–80% conversion, Figure 3i). Modification of Trp occurs at a 30-fold faster 165 
reaction rate than Cys the next most reactive.  Trp is a low-abundance residue and is highly likely 166 
to be found in the hydrophobic core of the protein. The ability of this method to trifluromethylate 167 
Trp selectively is a notable achievement.33 However, when targeting more common endogenous 168 
AAs for modification, strategies may rely on the modification of the most accessible and reactive 169 
copy of a repeated residue to achieve site-specificity.  170 
Due to their innate nucleophilicity, Lys residues represent one of the more abundant AAs 171 
(~6%) commonly targeted for protein modification.18 While Lys abundance can lead to extreme 172 
product heterogeneity with conventional modification methods (for example amidation with 173 
succinimide-based esters), the tertiary structure of proteins can enable higher levels of specificity 174 
as a result of unique, microenvironment-driven pKa changes.1,18,19 A recent study by Cravatt and 175 
coworkers observed and quantified the reactivities of 9,000 Lys residues in the human proteome, 176 
finding several hundred hyperreactive cases.18 Therefore, specific reagents or conditions have been 177 
developed to modify the most reactive Lys residues in different proteins. By adjusting the 178 
electrophilicity of Michael acceptors, our group has targeted the most reactive Lys residues in 179 
proteins while leaving other Lys and Cys residues untouched (1 equiv., 1-2 h, 25-37 ºC, pH 8.0, 180 
>95% conversion, Figure 3ii). The design of sulfonyl acrylate reagents was assisted by 181 
computational calculations that determined transition states facilitating the desired bond 182 
formation.12 Similarly, a multicomponent reaction involving formaldehyde, acetylene, and a Cu-183 
ligand complex as a catalyst was found to modify a single Lys residue in a handful of different 184 
proteins (100 equiv. aldehyde, alkyne, and CuI, 400 equiv. ligand, 72 h, r.t., pH 7.8, 40-99% 185 
conversion, Figure 3iii). Conveniently, the N-terminus is reversibly protected by the 186 
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formaldehyde, allowing for the reactive Lys residue to be targeted over the N-terminal amine. 187 
However, the kinetics for the multicomponent reaction are slower in addition to the suboptimal 188 
use of a Cu(I) catalyst that introduces potential toxicity and requires difficult purification steps.34 189 
Also reliant on the tertiary structure of target proteins are methods mediated by native 190 
metal- and ligand-binding sites. Such strategies manipulate the spatial arrangement of reagents and 191 
residues such that proximity promotes site-specific labeling. However, these methods rely on two 192 
factors: the native presence of a metal- or ligand- binding site and a nearby, reactive residue. If 193 
these conditions are met, then a substoichiometric amount of the catalytic targeting component can 194 
be used.35 For metal-binding sites, the most recent advances have relied on the use of Pd(II) for 195 
the arylation of Cys residues as exhibited with the site-specific modification of 196 
mannosyltransferase (80 equiv. Pd(II) reagent, 500 equiv. aryl halide, 4 h, 65 ºC, pH 7.6, >85% 197 
conversion, Figure 3iv).32 Further arylation techniques and products are discussed in this review, 198 
but a more in-depth and comprehensive review of this type of arylation has been published 199 
recently.36 Meanwhile, for ligand-binding sites, polyproline peptides targeting SH3 domain 200 
proteins were used to facilitate a reaction between Asp residues and aryldiazonium reagents (5 201 
equiv., 2.5 h, r.t., pH 7.4, 30% conversion, Figure 3v).19 Furthermore, targeting ligand-binding 202 
sites has also enabled the use of imidazole-1-sulfonyl diazotransfer reagents to convert 203 
surrounding amino groups into azide moieties for downstream bioorthogonal functionalization (1 204 
equiv. diazotransfer reagent, 100 equiv. Cu(II) catalyst, 1 h, r.t., pH 7.4, Figure 3vi).37 Methods 205 
have also been reported combining the use of metal reactivity and peptide binding sites for 206 
selective modification in SH3 domain proteins and antibodies. These metallopeptides consist of 207 
dirhodium(II) cores and either SH3 domain-binding (0.5 equiv. metallopeptide, 50 equiv. diazo 208 
compounds, 5 h, r.t., pH 6.2-7.4, >95%) or Fc-binding peptides (2 equiv. metallopeptide, 125 209 
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equiv. alkyne-diazo, 8 h, 10 ºC, pH 6.4, >90% conversion) for the production of functionalized 210 
protein and antibody conjugates (Figure 3vii).38,39 Other binding sites on antibodies have also been 211 
taken advantage of for proximity-induced site-specific modification. To avoid disrupting the Fc-212 
binding area (an important part of the antibody for receptor interaction), peptides that bind to the 213 
junction between two of the heavy chains in a full length antibody were mutated to contain 4-214 
fluorophenyl carbamate moieties and used to modify a lysine residue proximal to the junction (8 215 
equiv. binding protein, 48 h, 37 ºC, pH 8.5, >90% conversion).40 However, proximity-induced 216 
reactions can also be facilitated by strategies like a recently reported linchpin-directed method 217 
(LDM, 25 equiv. LDM reagent, 6-24 h, r.t. or 37 ºC, pH 7.0, 34-57% conversion).41 This LDM 218 
relies on a Lys-reactive group attached to a His-reactive group via a spacer. First, an intermolecular 219 
reaction allows for the Lys-reactive component of the LDM reagent to attach non-specifically and 220 
reversibly to the Lys residues in the target protein. Once the reagent is bound to Lys residues, the 221 
His-reactive component now has the opportunity to bind irreversibly and intramolecularly to a His 222 
in proximity of a bound Lys. The lysine residues are then released by the addition of an aminooxy 223 
reagent, leaving only the specific His residues modified.41 224 
Endogenous AA modification has also been achieved by disulfide rebridging, and several 225 
general techniques have been established. Conventional native Cys modification, often relies on 226 
the reduction of interchain disulfides followed by modification of the free Cys, but has the potential 227 
to cause protein instability due to the disruption of structure-stabilizing disulfide crosslinks.12 In 228 
disulfide rebridging methodologies, the disulfide bonds are reformed, and thus their structural 229 
function retained after modification. Additionally, disulfides that are selectively modified in these 230 
approaches tend to be found toward the exterior of the protein and have structure stabilizing 231 
functions, allowing internal disulfides that are vital for activity to remain protected.42 However, 232 
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the size and bulkiness of rebridging reagents must be limited to avoid disruption of the structure 233 
of the target protein. Recently, commercially available oxetane reagents have demonstrated the 234 
ideal distance for disulfide rebridging while also improving the stability and activity of therapeutic 235 
proteins and antibodies (20-60 equiv. oxetane, 6-12 equiv. tris(2-carboxyethyl)phosphine (TCEP), 236 
24-48 h, 25-37 ºC, pH 8.5, >95% conversion, Figure 3viii).43 Alternatively, unlike their bis-sulfone 237 
counterparts44, allyl sulfones have been proposed as viable disulfide rebridging reagents with high 238 
aqueous solubility and reactivity (2 equiv. allyl sulfone, ~1 equiv. TCEP, 24 h, r.t., pH 7.8, 19% 239 
and 28% isolated yield with insulin and lysozyme as model proteins, Figure 3ix).45 Meanwhile, 240 
divinylpyrimidine (DVP) was just reported as a stable rebridging agent for antibody and protein 241 
conjugates (10-15 equiv. DVP, 5 equiv. TCEP, 1-2 h, 37 ºC, pH 8.0, >95% conversion).46 A type 242 
of disulfide rebridging reagent for obtaining highly homogenous antibody drug conjugates (ADCs) 243 
with drug-to-antibody ratios (DARs) of 2 was reported: dibromopyridazinedione (dibromo-PBD) 244 
derivatives (16 equiv., 80 equiv. TCEP, 16 h, 4 ºC, pH 8.0, Figure 3x). To achieve this, one 245 
compound containing two dibromo-PBD derivatives connected by a linker crosslinks two disulfide 246 
bridges. Since there are four interchain disulfide bridges available in IgG antibodies, two such 247 
dibromo-PBD-linker compounds are used, each with one payload incorporated.47 Further reports 248 
of dibromo-PBD rebridging reagents for a “plug and play approach” for the production of ADCs 249 
and for the attachment of antibody fragments in a specific, favorable orientation to nanoparticles 250 
have been published recently.48,49 Even photomediated disulfide bridging has been explored using 251 
a one-pot thiol-yne conjugation strategy on a reduced antibody fragment (0.8 equiv. initiator, 1 252 
equiv. alkyne reagent, 4 h, 0 ºC, UV radiation (365 nm), 40% conversion, Figure 3xi). The method 253 
has proven applicable for a variety of alkyne reagents and has exhibited the potential of 254 
photomediated disulfide rebridging for therapeutic applications.50  255 
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Despite the potential of these discoveries, drawbacks remain prevalent: not being able to 256 
achieve high selectivity, homogeneity, efficiency, reagent stability, or conversion; not having 257 
control over the position of the conjugation site; and needing a multiple step synthesis to produce 258 
the reagents needed for the modification.32–34,38–42,45 The diversity between and within the classes 259 
of modification strategies (e.g. reactive-residue targeting, metal-/ligand-binding sites, disulfide 260 
rebridging, etc.) signifies that efforts to modulate and add functionality to proteins via endogenous 261 
AAs are becoming more pronounced and promising. When yields are optimized, such strategies 262 
have the potential for remarkable academic and industrial relevance as the protein of interest does 263 
not require prior sequence engineering. 264 
 265 
[H1] Modification via Genetic Manipulation 266 
 267 
The genetic engineering of proteins has proven to be an indispensable methodology for 268 
site-selective protein modification and the production of homogenous bioconjugates. Rather than 269 
working only with a scaffold of endogenous AAs, genetic engineering allows for the controlled 270 
introduction of a variety of abiotic and biotic chemical handles at designated sites.1 The potential 271 
versatility and generality inherent in the genetic engineering platform make these strategies 272 
invaluable for the exploration and modulation of protein function. The discussion of the various, 273 
genetically-based strategies that follows, focuses on the diversity and complementarity of the 274 
different method components and potential applications. Such diversity can be evaluated based on 275 
certain attributes: multiple modifications; biologically compatible conditions; reaction selectivity; 276 
directly added functionality vs. added bioorthogonal handle for subsequent modification; reaction 277 
efficiency and stability; method applicability; and modification reversibility. Additionally, the 278 
strategies presented here have been categorized into three broader insertion groups: canonical AAs, 279 
non-canonical (ncAAs), and motifs or enzymatic tags. 280 
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[H2] Canonical Amino Acid Insertion 281 
 While direct modification of endogenous AAs can be performed using the same chemical 282 
transformations discussed earlier in this section, these methods can often be more broadly applied 283 
and successful when the target residue is genetically inserted at specific positions in protein 284 
sequences. Although the selectivity is based primarily on chemical functionality, the insertion site 285 
in the protein is also of great importance: the site must be accessible to the modifying reagents and 286 
the protein must retain its structure and function. In addition, the insertion and expression of 287 
canonical AAs avoid disadvantages and complexities inherent to ncAA and non-AA motif 288 
insertion. As Cys has been the focus of many recently discovered methods due to its broad 289 
reactivity profile, this section has been split into two: methods targeting inserted Cys residues and 290 
methods targeting other low-abundance, endogenous residues.6 291 
[H3] Cysteine insertion 292 
 Out of the two most nucleophilic canonical residues (Cys and Lys), Cys remains the residue 293 
of interest largely due to its relative low abundance (~1.9%), high nucleophilicity, and ability to 294 
react in environments closer to neutral pH.17 Whether targeted as an endogenous AA or a mutated 295 
sidechain, Cys’s broad scope of reactivity from transfer (i.e. atom, electron, or hydride) and metal-296 
binding to exchange reactions indicates the incredible number of already determined Cys 297 
modification methods. Several recent reviews have focused on Cys-targeted conjugation.6,51 298 
Furthermore, Cys residues can be reduced to dehydroalanine (Dha) to extend the reach of an 299 
already versatile reactivity profile.6 The standard Cys reaction for efficiency and selectivity has 300 
until recently been maleimide-based reactions. However, due to the observation of retro-Michael 301 
additions under basic conditions and thiol exchange, in vivo therapeutic applications for maleimide 302 
linkages are slowly becoming replaced by more robust linkages. neglected.51 Even with the 303 
 14 
development of methods to stabilize the maleimide linkage by hydrolyzing the thiosuccinimide 304 
ring, these strategies prove to be less efficient and result in a mixture of hydrolyzed and non-305 
hydrolyzed products.52–58 Therefore, novel reagents with thiol-specific reactivity have been 306 
pursued that lead to irreversible, stable conjugation while attempting to reach efficiencies 307 
comparable to maleimide reactions. 308 
 While some of these recently discovered reagents add a unique chemical handle at the site 309 
of the inserted Cys residue for downstream functionalization, other methods manage to add 310 
functionality directly in a single step. Strategies for the efficient insertion of chemical handles 311 
include the addition of isobutylene (50-1000 equiv., 50 equiv. TCEP, 1-6 h, 4 ºC-r.t., pH 8.0-9.0, 312 
Figure 4i) and oxetane bromo-derivatives as electrophilic handles (1500 equiv. oxetane, 440 equiv. 313 
TCEP, 2-5 h, 37 ºC, pH 8.0-11.0, >95% conversion, Figure 4ii). Both electrophilic handles rely on 314 
a bromide leaving group for further modification by alkylation with small molecule nucleophiles. 315 
While the isobutylene handle facilitates conjugation under more biocompatible conditions, the 316 
oxetane linkage adds advantageous attributes to the conjugate by increasing aqueous solubility and 317 
metabolic stability.59,60 As electrophiles do not exist endogenously in proteins, these handles create 318 
unique sites on the protein for downstream functionalization. Meanwhile, other strategies focus on 319 
synthesizing modifying reagents that incorporate the desired functionality upon reaction with the 320 
protein.  321 
Even with the variety of reactive partners available for installed chemical handles, high-322 
yielding, simple, one-step processes for conjugation are hotly pursued.. Sodium 4-((4-323 
(cyanoethynyl)benzoyl)oxy)-2,3,5,6-tetrafluorobenzenesulfonate (CBTF) is  one reagent that 324 
fulfils these criteria. CBTF contains both an activated ester for amine functionalization prior to 325 
conjugation and a 3-arylpropiolonitrile moiety that can react with a  Cys residue. CBTF displays 326 
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a high potential for rapid reactions and forms  highly-stable products (12 equiv. CBTF, 1.1-2.2 327 
equiv. TCEP, 12 h, r.t., pH 6.8, Figure 4iii).61,62 Alternatively, by decorating the aromatic ring with 328 
a  variety of electron withdrawing groups (EWGs) and fluorine substituents, fluorobenzene type 329 
reagents have also been explored for the stable and selective S-arylation of Cys residues (2-67 330 
equiv., 16 h, 37 ºC, pH 8.3, Figure 4iv).63 Other reagents that form stable, irreversible linkages 331 
while also introducing desired functionality are: carbonylacrylic, allenamide, and cyclopropenyl 332 
ketone derivatives.15,64,65 Carbonylacrylic reagents succeed in performing the desired modification 333 
via a rapid Michael addition in a stoichiometric manner (1-50 equiv., 1-2 h, r.t.-37 ºC, pH 8.0, 334 
>95% conversion, Figure 4v).15 Allenamide reagents, being less electron deficient than ketones 335 
and esters, react specifically with Cys and avoid modification by common biological nucleophiles 336 
(10-25 equiv. allenamide, 10 equiv. dithiothreitol (DTT), 30 min, 37 ºC, pH 8.0, Figure 4vi).64 337 
Unlike the carbonylacrylic and allenamide reagents, the cyclopropenyl ketone derivatives, 338 
functionalized via amide connections formed by NHS-ester promoted reactions, rely on ring strain 339 
to promote irreversible, rapid formation of stable products (50 equiv. cylcopropenyl ketone, 5 340 
equiv. tris(hydroxypropyl)phosphine, 10 min, r.t., pH 6.0, Figure 4vii).65 Furthermore, 341 
dichlorotetrazine (10 equiv., 1 h, r.t., pH 5.2, Figure 4viii) and 2-azidoacrylate reagents (10 equiv., 342 
12 h, r.t., pH 7.4, >85% conversion, Figure 4ix) have been proposed as both being able to directly 343 
add functionality in one step in addition to introducing bioorthogonal sites for further 344 
functionalization.66,67 These dual functionalization strategies circumvent the need for two ncAA 345 
insertions and are very promising for improved theranostic applications.67 346 
In addition to the more conventional type Michael addition and alkylation reactions, metal-347 
based reactions have also been explored for the modification of Cys. However, transition metal-348 
based reactions have not been pursued to the same extent as metal-free methods due to common 349 
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difficulties with complex biomolecules: side reactions with endogenous protic, basic, or thiol-350 
containing moieties; heterogeneous product mixtures; catalyst deactivation; and incompatible 351 
protein modification conditions.68,69 Only recently has the specificity, efficiency, and versatility of 352 
transition-metal based chemistry been harnessed thanks to judicious metal and ligand choices.70 353 
Au(III) (15-20 equiv., 30 min, r.t., pH 8.0, Figure 4x) and Pd(II) complexes (1.1-10 equiv., 24 h, 354 
37 ºC, pH 8.5, >94% conversion, Figure 4xi) have been used for the production of stable S-arylated 355 
products by targeting Cys residues. The Au(III) and Pd(II) catalyzed systems are based on two-356 
electron strategies. The S-arylation products are stable and the conjugation irreversible, making 357 
these methods useful for many potential therapeutic applications. 68,70–72 358 
Reversible conjugation processes can, in the right context, be useful. These methods 359 
include the efficient Michael addition of either 5-methylene pyrrolones (5MPs, 200-500 equiv., 2 360 
h, 37 ºC, pH 7.5, Figure 4xii) or 4-acetoxy cyclopentenones (50 equiv., 1-2 h, r.t., pH 7.0-7.4, 22-361 
95% conversion, Figure 4xiii) with controlled release by increasing pH/thiol exchange or Michael 362 
donor addition respectively; the formation of a thiazolidino boronate (TzB) product at N-terminal 363 
Cys residues by 2-formyl phenylboronic acid (2-FPBA) that dissociates in slightly acidic 364 
environments (this particular case shows modification of native N-terminal Cys, 1 equiv., 30 min, 365 
r.t., pH 7.0, >95%, Figure 4xiv); and the formation of a thioether bond by a fast reaction driven by 366 
irradiation at 350 nm of 3-(hydroxymethyl)-2-napthols (napthoquinone methide precursors, 367 
NQMPs) that can be reversed by irradiation of a dilute solution of labeled conjugate or when mixed 368 
with vinyl ether (8-9 equiv., 2-6 min, r.t., pH 7.4, 350 nm irradiation, Figure 4xv).73–77 Such 369 
variable processes for controlled release of a Cys residue can lead to information on critical 370 
epigenetic roles or reversible modulation of protein function.73,76 Additionally, the acidic 371 
environment-driven release of 2-FPBA could be used for endosomal release and delivery of 372 
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cytotoxic drugs from an antibody drug conjugate (ADC) construct. Furthermore, combinatorial 373 
approaches using these methods have an impact in the field. For example, NQMP-Cys conjugation 374 
is orthogonal to standard azide–alkyne click chemistry, allowing for many nuanced, complex 375 
reversible and release/catch applications.74,75 376 
The methods discussed here only cover a fraction of the applications possible through 377 
targeted Cys conjugation alone. Even with risks of disulfide disruption or shuffling due to 378 
reduction steps required to produce free Cys thiols, the Cys-based modification strategies pursued 379 
by scientists represent a window into the future goals of the site-selective protein modification 380 
field. The ultimate goal is to obtain a complete toolkit of strategies that cover everything from 381 
transition metal-mediated to photoinitiated processes that can allow for dual or reversible 382 
modification that can be used in concert with other (orthogonal) methods. Cys modification 383 
symbolizes the key concept of site-selective protein modification: the strength and power of the 384 
technique is a result of  the complementarity inherent in a substantial variety and number of 385 
methods. 386 
[H3] Other Low-Abundance Canonical Amino Acids 387 
 388 
To supplement engineered Cys residue modification, methods targeting alternative, low-389 
abundance AAs have been explored. Genetically inserted residues that have captured particular 390 
interest are: Trp, Tyr, Met and His. Apart from all four being of relative low-abundance to other 391 
canonical AAs, endogenous Met and Trp residues are also most commonly found in the 392 
hydrophobic interior of the protein.78,79 Both low abundance and positioning can increase the 393 
likelihood that a genetically inserted copy is the only instance of that residue available for 394 
modification. In other words, genetic manipulation can allow for the formation of a unique 395 
chemical handle. However, due to the lower reactivity of these four sidechains in comparison to 396 
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residues such as Cys and Lys, more extreme or biologically incompatible conditions were initially 397 
relied upon.79,80 While not all of the methods for modifying these less reactive, low-abundance 398 
residues require metal mediation,  it is a common approach that can ensure specificity and avoid 399 
the need for highly reactive reagents which may lead to unwanted modification elsewhere on the 400 
protein..81,82  401 
Two methods reported in the last five years, one metal-mediated and the other 402 
organoradical-based, target Trp residues.79,83 The metal-mediated method for Trp uses 403 
1-[(triisopropylsilyl)ethynyl]-1,2-benziodoxol-3(1H)-one (TIPS-EBX). Catalyzed by 404 
[AuCl(SMe2)], the hypervalent iodide TIPS-EBX adds regioselectively to the Trp indole (10 equiv. 405 
TIPS-EBX, 5 equiv. catalyst, overnight, r.t., ~90% conversion, Figure 5i), rendering this the first 406 
Trp modification method both selective for Trp and able to modify a specific site on Trp residues 407 
(i.e. modification occurs at Trp C2).83 Meanwhile, the reagents used for the organoradical, 408 
selective modification of Trp are derivatives of 9-azabicyclo[3.3.1]nonane-3-one-N-oxyl (keto-409 
ABNO). Stabilized on the oxygen bonded to the nitrogen, the radical adds to the indole ring of Trp 410 
to achieve a highly homogenous product (1-5 equiv. keto-ABNO, 0.6-3 equiv. NaNO2, 30 min, 411 
r.t., pH 7.4, 11-64% conversion, Figure 5ii).79 Based on some drawbacks to these methods, 412 
including the acidic conditions required for high conversion with keto-ABNO conjugation, metal-413 
mediated strategies act as valuable alternatives for proteins and applications requiring alternate 414 
conditions.79 415 
Metal-mediation is also required for certain Tyr-selective modification strategies. As the 416 
more polar Tyr tends to be at the protein surface, site-specificity is somewhat harder to achieve. 417 
However, due to low abundance, even in the case of multiple Tyr modifications, high product 418 
homogeneity is still likely.84 In one instance, iron-containing hemin was reported to catalyze the 419 
 19 
addition of N-methylated luminol derivatives to the ortho Tyr position in the presence of H2O2 (1 420 
equiv. hemin, 100 equiv. peroxide, 100 equiv. luminol derivative, 1 h, r.t., pH 7.4, Figure 5iii). 421 
The production of a reactive cyclic diazodicarboxyamide intermediate in situ drives the reaction 422 
forward.84 A similar intermediate has been used as the starting reagent for Tyr modification, but 423 
the hemin-mediated method avoids the need to store unstable reagents.84,85 Whether through 424 
coordination or covalent binding, some methods require direct metalation of the protein rather than 425 
metal mediation of the modification. A method for Tyr modification has been established recently 426 
that uses rhodium(III) chloride and boronic acid to link arene complexes to the ortho position in 427 
Tyr (50 equiv. rhodium(III) chloride and boronic acid, overnight, r.t., pH 9.4, Figure 5iv). The 428 
Rh(III) Tyr complexes maintain both a metastability and controlled reversibility (via DTT or H2O2) 429 
due to the inorganic linkage.86 Although still not as highly regarded as metal-free methods, 430 
advantages of metal-based reactions have become more apparent and have led to further 431 
exploration of novel, specific interactions. 432 
Although they are not yet able to augment protein functionality (aside from facilitating 433 
transition metal complex interactions to induce luminescence), methods selectively targeting His 434 
with Pt(II) (5 equiv. complex, 1 h, r.t., pH 7.0, Figure 5v) and Ru(II) (excess complex, 30 min, r.t., 435 
pH 7.0, Figure 5vi) complexes have been developed for protein labeling and staining. While the 436 
interaction between the complexes and His residues has not yet been identified as covalent or 437 
noncovalent as a result of conflicting analysis results, the staining or “switch-on” probe protocols 438 
developed with these complexes only require 30 min – 1 h to reach completion.81,82 As transition 439 
metal complexes usually bind nonspecifically to proteins, these complexes may signify new 440 
interactions inspire novel site-selective modification methods. Aside from Trp-, Tyr-, and His-441 
selective methods, a redox activated tagging (ReACT) Met-targeted reaction was also reported 442 
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using oxaziridine reagents (1.1-10 equiv., 10 min, r.t., pH 7.4, >95% conversion, Figure 5vii). 443 
Oxaziridine reagents have demonstrated selective oxidation of Met residues to sulfimides, which 444 
can then be used as a chemical handle for installing payloads.78 Similarly targeting Met, 445 
hypervalent iodine species were used to create a high energy sulfonium protein synthon (500-1667 446 
equiv. iodonium salt, 200-667 equiv. thiourea, 50-167 equiv. TEMPO, 50-167 equiv. formic acid 447 
(~pH 3), <5 min, 0-20 ºC, 84-95% conversion). While functionalization is possible upon oxidation 448 
of Met by incorporating the desired functionality into the iodonium salt, the resulting sulfonium 449 
product also has an electrophilic diazo group that allows for further modification.87 450 
Outside of the proteinogenic, canonical AAs, selenocysteine (Sec) has also made an 451 
appearance quite recently in reports of site-specific protein modification (oxidation of Sec: 20 452 
equiv. 2,2’-dithiobis(5-nitropyridine), 15 min, r.t., acidic conditions, not isolated; arene addition: 453 
10 equiv. arene, 5 h, 37 ºC, pH 8.0, 23% isolated yield).88 This report acknowledges the ability for 454 
electron-rich arenes (e.g. vancomycin) to attach at the site of an oxidized Sec residue, containing 455 
an electrophilic Se-S bond. While modification of the oxidized Sec was shown directly in an 456 
affibody, the insertion into the full length antibody was accomplished with a sortase A mediated 457 
method. 88 Even so, this method shows promise for direct modification of the oxidized Sec in full 458 
length antibodies and larger proteins. All of the methods in this section, while creating novel 459 
solutions and tools to unlock unexplored directions, represent an ongoing battle against lower 460 
reactivity, lower conversion, and lower selectivity when attempting to target inserted, low-461 
abundance AAs (with the exception of Cys).  462 
 463 
[H2] Noncanonical Amino Acid Insertion 464 
 465 
 One of the most reliable methods to achieve site-specificity for protein modification 466 
involves the genetic insertion of ncAAs, containing either unique abiotic or biotic functionalities 467 
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for subsequent bioorthogonal reactions. In the 1960’s, translation of the genetic code was thought 468 
to be rigid, but the discovery of selenocysteine (Sec) and pyrrolysine (Pyl) indicated an inherent 469 
flexibility.89 Schultz and coworkers spearheaded the movement toward the broadly applicable use 470 
of mutually orthogonal tRNA/aminoacyl-tRNA synthetase (RS) pairs (i.e. no native RS 471 
aminoacylates the orthogonal tRNA and no naturally occurring tRNA is modified by the 472 
orthogonal RS) for recognizing and inserting ncAAs at the site of the amber nonsense codon in E. 473 
coli.90–93 The amber nonsense codon (i.e. UAG) was chosen as a model method due to efficient 474 
incorporation with low levels of error.89 With such promising foundational methods established, 475 
protein modification via genetically inserted ncAAs has progressed both in insertion methodology 476 
and the inclusion of novel reactive groups (Figure 6). 477 
Methods for the insertion of ncAAs aside from orthogonal aminoacyl-RS/tRNA pairs for 478 
amber suppression have been developed over the past few years. These incorporation strategies 479 
have focused on the reassignment of the rare arginine-tRNA sense codon (AGG); DNA 480 
hybridization chromatography for depletion and replacement of certain tRNAs; a cell-free 481 
translation system with in vitro transcripts of tRNA; and engineered orthogonal ribosomes.89,94–96 482 
However, to be incorporated into a protein, the ncAA must be synthesized. A review has recently 483 
been published on strategies being developed to make this synthetic process more effective.97 484 
While the method of insertion is crucial for expression efficiency and performing multiple 485 
insertions, the abiotic, bioorthogonal chemical handles incorporated by ncAAs represent a critical 486 
method for the furthering of site-selective protein modification. Because of the insertion of unique 487 
chemistries that respond to a specific reactive partner and are inert to native entities in biological 488 
environments, clean and efficient reactions in cells, direct functionalization of the ncAA with click 489 
chemistry, and the precise placement of PTM mimics have been performed. The breadth of 490 
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applications and functionalities based on the genetic incorporation of ncAAs is such that we have 491 
only discussed here examples that we consider to be the most representative of the 492 
accomplishments of this strategy. accomplishments 493 
Recently, chemistries have been explored to install accurate PTMs or chemical handles for 494 
subsequent crosslinking.98,99 Site-selectivity is vital for the evaluation of specific PTMs, as these 495 
epigenetic modifications have different consequences when translated by corresponding “reader” 496 
proteins in varying contexts.100 Understanding the role of certain PTMs, especially in histone 497 
proteins, can be accomplished through ncAA insertion. Such insertions help decode protein–498 
protein interactions (PPIs), including those necessary for gene regulation and apoptosis.92 A novel 499 
ncAA, ε-N-2-hydroxyisobutyryl-Lys (HibK), representing a PTM observed in histones, was 500 
recently incorporated in histone proteins using an orthogonal amber suppressor pyrrolysl-RS pair 501 
(3.6-11.9 mg/L expression yield). By altering the charge of the Lys residue and adding steric bulk, 502 
site-specific insertion of HibK will help determine how the PTM affects chromatin structure.101 503 
Additionally, PTMs can be inserted in protected forms if the native form is unstable or too reactive. 504 
Phosphotyrosine (pTyr) was inserted as a neutral analog that is both cell permeable and stable in 505 
cells (1.0-1.75 mg/L expression yield). Acidic conditions were used to reveal the native 506 
phosphotyrosine (16-48 h, 4 ºC, pH 1.0-2.0).102 Similarly, a protected allysine residue in the form 507 
of e-N-(4-azidobenzoxycarbonyl)-d,e-dehydrolysine (AcdK) was inserted into histone proteins 508 
and epigenetic enzymes (7.0 mg/L expression yield). The AcdK undergoes reduction by 509 
phosphines to reveal allysine (TCEP, 2 h, r.t., pH 7.0), which hydrolyzes and is modified by 510 
reductive amination (NaCNBH3, 8 h, r.t., pH 7.0) to insert either monomethyllysine or 511 
dimethyllysine.103 Both lysine-methylation and phosphorylation PTMs have significant impact on 512 
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cell cycle progression and development, and ncAA insertion has provided methods to facilitate 513 
their comprehension.  514 
Unlike the aforementioned examples, novel photo-lysine ncAAs can insert photo-515 
derivatives (4-40% incorporation), containing diazirine rings, of lysine-based PTMs. These 516 
derivatives both approximate and identify possible native PPIs. The method has yet to be 517 
demonstrated in a site-specific manner, but a residue specific manner based on growing cells in 518 
media containing photo-lysine has confirmed its potential for selective Lys replacement in native 519 
proteins. Noncovalent, transient PTM interactions can then be captured by covalent bonds formed 520 
after the photo-cross-linking of the inserted photo-lysine and the protein of interest (1 equiv., 30-521 
60 min, 25-37 ºC, pH 7.5, 365 nm irradiation).13 Such cross-linking methods also represent an 522 
alternative application for ncAAs: the insertion of chemical handles for subsequent 523 
functionalization. 524 
The ability of ncAA insertion to install reactive groups that enable bioorthogonal 525 
functionalization has been invaluable to site-selective protein modification research. Chemical 526 
handles recently inserted into proteins include: fluorine-activated aryl carbamates (FPheK, 3-8 527 
mg/L expression yield), aryl isothiocyanates (pNCSF, 8-16 mg/L expression yield), and thioester 528 
derivatives of Asp acid (ThioD, 8 mg/L expression yield).104–106 FPheK, once inserted into a 529 
protein, reacts with amines, thiols, and phenols to produce intra- or inter-molecular cross-linking 530 
(2 equiv. nucleophile, 8 h, 37 ºC, pH 8.5).104 Similarly, pNCSF forms urea-type, cross-linking 531 
bridges between proteins or between proteins and small molecules (3-100 equiv. amine-containing 532 
nucleophile, 3-24 h, 37 ºC, pH 7.4-8.5).105 Meanwhile, ThioD can be modified by amine-based 533 
nucleophiles (100 equiv. nucleophile, 20 h, 37 ºC, pH 7.4).106 While these insertions broaden the 534 
scope of reactive groups available for modification in proteins, the sequential steps and long 535 
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modification reaction times are suboptimal. Photo-mediated methods can circumnavigate these 536 
limitations by requiring less time and avoiding the use of excess reagents.98  537 
The most recent ncAAs developed for photo-mediation post insertion are 2-aryl-5-538 
carboxytetrazole-lysine derivatives (ACTKs, 0.8 mg/L expression yield, 15 min, UV radiation 302 539 
nm), benzyloxycarbonyl-lysine derivatives (AmAzZLys with an amine and azide functionality, 53 540 
mg/L expression yield, 15 min, UV radiation 365 nm), and photoswitchable click AAs (PSCaas 541 
equipped with azobenzenes modified with an alkene, ketone, or chloride; 1.2-1.8 mg/mL 542 
expression yield; 2 min; 365 nm).107–109 While AmAzZLys and PSCaas both need further chemical 543 
modification in addition to photo-cross-linking or conformation change via photoswitching, these 544 
strategies still represent a progression toward photo-based reactions in this research field.107,108 Of 545 
all the strategies discussed here, the insertion of photo-lysine represents most clearly the overall 546 
direction ncAA insertion strategies are moving. As an elegant insertion of multifaceted 547 
functionality capable of providing information both on PTMs but also for photo-cross-linking and 548 
modification, the insertion of photo-lysine has the potential for many applications, especially once 549 
site-specific insertion of these ncAAs has been achieved.13  550 
[H2] Motif Insertion and Enzymatic Methods 551 
 To circumvent the synthesis and expression of ncAAs while retaining high levels of 552 
specificity, canonical AA motifs have been designed for insertion into protein sequences to modify 553 
specific residues. The target residue in the motif is activated by microenvironment manipulation 554 
based on the identity of the surrounding AAs or recognition of the motif by a specific 555 
enzyme.3,11,110 Several reviews on enzymatic methods for site selective protein modification have 556 
been published recently.111,112 Thus, the limitations inherent in targeting ncAAs or native residues 557 
based on chemical functional group alone can be overcome. However, the size and position of the 558 
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inserted motif can cause challenges. In some cases, motifs can only be added at the extremities of 559 
proteins due to need for increased accessibility or are large enough that insertion compromises 560 
protein activity.113,114 While the inherent specificity of enzymatic modification is a substantial 561 
advantage, the enzyme must be easily obtained and achieve high conversions to be industrially 562 
useful.3 563 
 Based on the advantages of motif insertion, studies exploring novel fusion proteins as well 564 
as enzymatic tags have been reported recently. Even though fluorescent proteins, such as 565 
SNAP-tag, HaloTag, and CLIP-tag, have been proven valuable for fusion to termini of target 566 
proteins, the attachment of a whole protein may disrupt activity.115 Therefore, shorter fusion tags, 567 
such as fluorophore-binding peptides (i.e. “fluorettes”), have taken precedence. A method to install 568 
TexasRed covalently to a target protein was recently reported using a TexasRed fluorette, TR512 569 
(1.5-4 equiv. probe, 10-40 equiv. TCEP, 30-60 min, 37 ºC, pH 7.9, 76% conversion, 34-AA tag, 570 
Figure 7i). The fluorette was added to the N-termini of target proteins via linkers of two Cys 571 
residues to ensure covalent binding to TexasRed promoted by proximity.116 While this strategy 572 
relies on exclusive fluorette specificity to certain fluorophores, other inserted motifs have more 573 
general applications.  574 
 A broader substrate range for more general modification is possible with enzyme-575 
mediation (e.g. tubulin Tyr ligase – TTL – and trypsiligase).114,117,118 TTL attaches Tyr derivatives 576 
to the C-terminal residue in an inserted Tub-tag at the C-terminus of the target protein (200 equiv. 577 
substrate, 0.02-0.2 equiv. TTL, 1-3 h, 37 ºC, pH 7, 99% conversion,14-AA tag, Figure 7ii).114 578 
Meanwhile, due to reversibility often observed in enzymatic reactions, the proteinase trypsiligase 579 
can also be used for ligation. While competing hydrolysis reactions generally limit this activity, 580 
an activation domain on trypsiligase that only allows proteinase activity when interacting with 581 
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specific substrates (i.e. “substrate-activated catalysis”) allows for promotion of the ligase activity. 582 
Therefore, the YRH recognition tag for trypsiligase can be inserted at the N-terminus of the target 583 
protein, the Y-R bond broken, and the guanidinophenyl ester derivative (OGp) added (first step: 584 
0.05 equiv. trypsiligase, 0.5 equiv. Zn(II) additive, 1-18 h, second step: 3-5 equiv. OGp, 30-60 585 
min, 4-20 ºC, pH 7.8, >95% conversion, 3-AA tag, Figure 7iii).118 While still limited to 586 
modification at the protein extremities, a diverse population of substrates can be used, and the 587 
specificity of the enzyme can lead to higher likelihood of orthogonality with other modification 588 
methods.  589 
 Due to the recent discovery of short sequences that each feature a particularly reactive 590 
amino acid (i.e. “clever” peptides), enzymes are sometimes unnecessary for site-specific 591 
modification directed by motif insertion. Most recently, the activation of specific Cys residues for 592 
modification by aza-dibenzocyclooctyne (DBCO), 2-cyanobenzothiazole (CBT), and 593 
perfluoroaromatic reagents have been reported.14,119,120 The DBCO-tag facilitates modification of 594 
a Cys residue by DBCO derivatives at either terminus of a target protein. Thiol–yne reactions have 595 
gained interest recently as an underdeveloped click reaction but have struggled with site-596 
specificity, the use of a tag enables a more selective and rapid reaction to occur (20 equiv. DBCO, 597 
20-100 equiv. DTT, 4-16 h, 37 ºC, pH 8.0, 80-90% conversion, 7-AA tag, Figure 7iv).119 Similarly, 598 
the fusion tag targeting Cys-CBT reactivity, installed at the N-terminus, avoids protection or 599 
proteinase steps prior to modification (100 equiv. CBT, 200 equiv. TCEP, 1 h, 37 ºC, pH 7.4-8.5, 600 
12-71% conversion,11-AA tag, Figure 7v).120 Meanwhile, the π-clamp for the targeting of Cys-601 
perfluoroaromatic reactivity achieved the goal of site-specificity with only 4 AAs in the motif (20-602 
26 equiv. perfluoroaromatic, 400 equiv. TCEP, 2-6 h, 37 ºC, pH 8.0, >95% conversion, 4-AA tag, 603 
Figure 7vi). Based on computationally calculated peptide conformations and energy pathways, the 604 
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perfluoroaromatic reagents are hypothesized to be recognized by the phenylalanine residues, 605 
bringing the reagent into the vicinity of the activated Cys.14 Recently, another Cys activation-based 606 
tag (Dis-tag) was reported that differentiates between free Cys and disulfide bond reactivity, 607 
allowing for the free Cys to first be modified with a maleimide reagent followed by the reduction 608 
and rebridging of the disulfide bond (6-AA tag, free Cys modification: 2 equiv. maleimide reagent, 609 
overnight, 15 ºC, pH 7.4, 75% conversion; disulfide rebridging: 2 equiv. allyl sulfone reagent, 2 610 
equiv. TCEP, 24 h, 15 ºC, pH 7.8, 55% conversion). The Dis-tag allows more facile access to dual 611 
modifications by incorporating both sites for modification within a 6-residue minimal distance.121 612 
With no need for enzymatic mediation, the potential for insertion and modification of these Cys 613 
residues at in-chain positions is higher based on the easier access of smaller molecules to sterically 614 
hindered sites. 615 
 To complement Cys-targeted methods, motifs that target Lys residues have also been 616 
developed. Cyclohexene sulfonamide reagents are known to modify a specific Lys residue (Lys64) 617 
over all other endogenous Lys residues in human serum albumin (HSA). Therefore, the specific 618 
domain, HSAdI, has been fused to protein termini as a reactive platform for Lys site-specific 619 
modification (1-50 equiv., 2-24 h, 37 ºC, pH 7.4, 197-AA HSAdI, Figure 7vii).115  620 
In a similar fashion, the unusual activity of the enzyme sortase A has been used to mediate the 621 
formation of an isopeptide bond between the e-amino group of a Lys residue in an inserted pilin 622 
domain with the threonine carboxyl group from an LPXTG (where X = any AA) tag-containing 623 
substrate. (10-100 equiv. LPXTG-containing substrate, 2 equiv. enzyme, overnight, 32 ºC, 75% 624 
conversion, 11-AA domain, Figure 7viii).122  625 
Beyond the targeting of Cys and Lys residues, a recently reported method targets a His-Gly-His 626 
(His2-tag, 1-5 equiv. PEGylated bis-sulfone, 16 h, 20 ºC, 28-39% conversion, 6-AA tag).123 With 627 
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no need for metal chelation, bis-sulfone modified PEG chains were shown to selectively modify 628 
the two inserted His residues in the tag over other His residues in the protein due to their close 629 
proximity. Performing the reaction at pH = 5 avoids modification of other residues and, combined 630 
with the low abundance of His, leads to high levels of selectivity. 123  631 
 Even with the discovery of novel activities of known enzymes, enzymatic methods learned 632 
previously are most commonly optimized by the positioning and length of the recognition tag. In 633 
several cases, enzymatic recognition tags have been shortened or adjusted to create more reactive 634 
microenvironments.124,125 In others, methods have been effective in various positions within the 635 
protein structure, allowing for multiple tag insertions without affecting protein activity.113,125 Even 636 
the choice of slightly different reagents and methodology can allow for higher control over product 637 
identity as well as the option for a reversible conjugation.126 Furthermore, the kinetics of enzymatic 638 
recognition and transformation, such as for sortase A, can be manipulated and improved through 639 
engineering an intramolecular reaction.127,128 Successful attempts at one-pot processes have also 640 
been performed using several enzymes either in a tandem reaction to fine-tune the resulting 641 
modification or in a simultaneous, dual modification based on orthogonal recognition tags.129,130 642 
Even with these improvements, the discovery of the π-clamp represents an influential benchmark 643 
in this field. This elegant, short, and computationally designed motif accomplishes efficient 644 
modification at protein termini and shows promise for in-chain position insertion.14 Such attributes 645 
indicate future studies will most likely include: heavier emphasis on computational methods and 646 
creative manipulations of microenvironments rather than randomized peptide assays for the 647 
discovery of novel insertion motifs. 648 
 649 
[H1] Downstream Functionalization 650 
 651 
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When direct modification of protein sequence is not possible, functionalization can be 652 
achieved by inserting or attaching areactive functional group  (“a chemical handle”). An entire 653 
class of selective bioorthogonal reactions has been developed for this purpose and has been 654 
promoted by the introduction of ncAAs. This diverse class of reactive pairs has been critical for 655 
installing unique functionalities in proteins. If insertion of a specific ncAA proves challenging due 656 
to limited cellular machinery, chemical handles might also be installed by enzymatic or chemical 657 
modification of a residue – though this is less attractive purely by virtue of requiring two synthetic 658 
steps. Therefore, the toolkit for efficient protein modification is augmented by both new methods 659 
for ncAA insertion and also the discovery of new bioorthogonal reactions.  660 
However, with each major development, limitations and problems have arisen. The use of 661 
large protein tags (e.g. GFP) risks affecting protein activity post conjugation,  and the introduction 662 
of copper-catalysed azide–alkyne cycloaddition (CuAAC) allowed the attachment of small 663 
molecule tags. The CuAAC is one example of “click chemistry” — chemistry defined by high 664 
reaction and conversion rate, green solvent systems, low levels of byproducts, and broad functional 665 
group applicability.131–133 The potential toxicity of Cu(I), led to the development of strain-666 
promoted (and copper-free) azide–alkyne cycloaddition (SPAAC).133,134 In attempts to further 667 
improve the reaction kinetics, inverse-electron-demand Diels–Alder (IEDDA) reactions were 668 
developed.134 Reaction rate is a highly important criterion in the development of bioorthogonal 669 
reactions (rates span from 10-5 M-1 s-1 to 105 M-1 s-1) — molar substrate concentrations can be 670 
naturally limited when dealing with large molecular weight biomolecules and in the case of 671 
radiolabelling experiments reactions must be completed before decay is complete.  . However, 672 
more reactive agents used to achieve faster reactions were also observed to be less stable (e.g. 673 
trans-cyclooctyne – TCO – and tetrazine derivatives).135–137 Increased reaction rate and reactivity 674 
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also generally led to difficulties with complementary bioorthogonal reactions for multi-site 675 
modification.137 Therefore, bioorthogonal reactions must be designed keeping in mind competing 676 
needs for high reaction rates and for reagents to stable in biological environments, which differ 677 
from those simulated with in vitro testing.131 678 
To expand the toolkit of bioorthogonal reactions available, novel reaction partners have 679 
been reported with comparable reaction rates and increased stability relative to already discovered 680 
methods. Most of these recent methods take advantage of alkyne or aldehyde reactivity. Based on 681 
SPAAC, a strain-promoted oxidation-controlled cyclooctyne-1,2-quinone cycloaddition (SPOCQ) 682 
was established to add temporal control to the reaction. Using periodate oxidation, 1,2-catechols 683 
are oxidized to 1,2-quinones that perform SPOCQ cycloaddition with the strained alkyne 684 
bicyclo[6.1.0]nonyne (BCN) as an inserted ncAA (4 equiv. quinone, 1 h, r.t., pH 7.4, 90% 685 
conversion, k = 496 ± 70 M-1 s-1, Figure 8i).138 Also using an inserted BCN ncAA, phenyl sydnones 686 
with a 1,3-dipole were shown to undergo a [3+2] cycloaddition to produce a stable pyrazole 687 
functionality (50 equiv. sydnone, 6 h, 37 ºC, pH 8.0, >95% conversion, k = 0.054 ± 0.00067 M-1 688 
s-1, Figure 8ii). Although slower than SPOCQ, the sydnone-BCN reaction does display comparable 689 
rates to SPAAC and cross-metathesis reactions.135 An alkyne functionalized ncAA can be coupled 690 
with a second, alkyne functionalized reactant using a  Glaser–Hay couplingproducing a linear, 691 
stable diyne product (10 equiv. alkyne, >50 equiv. CuI/tetramethylethylenediamine, 4-6 h, 4 ºC, 692 
71-93% conversion, Figure 8iii). Glaser–Hay couplings have recently been optimized for use in 693 
an aqueous environment, with the installed diyne product amenable to further 694 
modification.139Using a similar ncAA handle, ruthenium catalysed alkyne hydrosilylation has 695 
recent been used to form a C–Si bond (10-300 equiv. hydrosilane, 0.05-4.5 equiv. catalyst, 2-24 h, 696 
37 ºC, pH 7.4-8.0, 45-50% conversion, k = 1.0 M-1 s-1, Figure 8iv). The gem-disubstituted 697 
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vinylsilane product lends itself to additional modification, and the overall reaction is 698 
complementary to hydrazone formation, allowing for multiple modifications.140  699 
Aldehyde and ketone reactive handles offer selective reactions and are widely tolerated 700 
electrophiles, and on this basis interest in the use of hydrazone and oxime linkages has grown.141 701 
Many biological applications require highly stable products and thus C–C bond forming reactions 702 
are desirable.142 Based on this reasoning, two Knoevenagel-type condensations were reported: 703 
trapped (8 equiv. pyrazolone reagent, 16 h, 37 ºC, pH 5.5, k = 0.20 M-1 s-1, Figure 8v) and tandem 704 
(8 equiv. pyrazolone, 16 h, 37 ºC, pH 7.2, Figure 8vi). Both target a formylglycine (fGly) residue, 705 
inserted by formylglycine generating enzyme (FGE).143,144 Also targeting C–C bond formation, a 706 
direct aldol reaction of 2,4-thiazolidinediones with an N-terminal aldehyde (itself produced by a 707 
sodium periodate oxidation of a 1,2-aminothiol moiety) was also successful (1000 equiv., 3 h, 37 708 
ºC, pH 6.5, 83% conversion, k = 0.0078 M-1 s-1, Figure 8vii).145 An aldol ligation reaction catalysed 709 
by an L-proline derivative was reported (2-20 equiv. aldehyde, 100-500 equiv. catalyst, 1-6 h, 37 710 
ºC, pH 7.5, >95% conversion, k = 24 M-1 s-1, Figure 8viii). The aldehyde functionality was inserted 711 
as a protected analogue via a thiazolidine-Lys (ThzK) ncAA, allowing for both in-chain and 712 
extremity modification. An additional aldehyde functionality was then needed to complete the 713 
organocatalyst-mediated protein aldol ligation (OPAL) reaction. OPAL products can then be 714 
further modified through oxime ligation.142  715 
Methods outside alkyne- and aldehyde-based reactions have also been reported. Generally, 716 
the incorporation of a new ncAA allows for these new protocols to be developed. One such ncAA 717 
is N-acryloyl-Lys (AcrK). Alkyl phosphine reagents were used to modify AcrK through a 718 
phospha-Michael addition, which occurs at a faster rate than thiol addition as phosphine reagents 719 
have been used to activate electrophiles in thiol-ene reactions (30-40 equiv., 1-5 h, 25-37 ºC, pH 720 
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6.8-8.8, 80-90% conversion, k = 0.06 ± 0.01 M-1 s-1, Figure 8ix).146 A quadricyclane (QC)-721 
containing ncAA has also been successfully inserted into proteins. The strained, hydrocarbon 722 
reagent was functionalized with nickel bis(dithiolene), leading to a QC ligation cleavable by UV 723 
irradiation and orthogonal to common reactions with aldehyde/aminooxy and alkyne/azide pairs 724 
(1-2 h, r.t., pH 7.4, Figure 8x).147 Lastly, the reaction between cyclopropenones, inserted as ncAAs, 725 
and triarylphosphines was shown to produce a,b-unsaturated amides (20 equiv., 1-4 h, 37 ºC, pH 726 
7.0, >95% conversion, k ³ 20 M-1 s-1, Figure 8xi).148,149 The introduction of reversibility and 727 
orthogonality into bioorthogonal reactions paves the way for traceless or multi-site conjugation 728 
applications. In particular, the increase in bioorthogonal reactions discovered raises the likelihood 729 
for complementary/orthogonal reactions to achieve multiple, distinct modifications. 730 
In addition to “click-type” reactions, accurate approximations of PTMs can be installed 731 
using methods established for the modification of Dha, which is itself commonly installed by the 732 
reduction of an inserted Cys residue.6,150 PTMs have also been inserted based on synthetic and 733 
ncAA methods. The synthetic approach is inconvenient as the PTM can only be incorporated easily 734 
into shorter peptides, and the insertion of ncAAs involves being able to obtain the appropriate 735 
genetic machinery.151 Thus, the formation and modification of Dha is a much more attractive 736 
option.  As Dha insertion marks the addition of an electrophilic moiety, a type of functional group 737 
not endogenous to proteins, novel methods to modify Dha sidechains at both terminal and in-chain 738 
positions have been ardently pursued.152 Most recently, aza-Michael additions have been 739 
demonstrated with amine-based nucleophiles to produce secondary and tertiary amine products 740 
(>300 equiv., 1-4 h, 25-37 ºC, pH 8.0-9.0, 40-95% conversion, k = 6.1 ´ 10-5 M-1 s-1, Figure 741 
8xii).153,154 These reactions avoid the use of thiol-based nucleophiles to avoid risking the disruption 742 
of surface disulfide bonds. While these C–N bonds are representative of a common trope in nature 743 
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and stable between pH 2.8-12.8, more accurate representations of PTMs need to be attached by C–744 
C bonds at the site of Dha modification.153 Two recently proposed radical-based mechanisms were 745 
offered as solutions. The first used an alkyl-halide (either iodide- or bromide) for the initiation of 746 
radical species combined with NaBH4 for the prevention of unwanted oxidation and disubstitution 747 
(100-2000 equiv. alkyl-halide, 30 min, 4 ºC, pH 4.0-8.0, Figure 8xiii). Sidechains from nonpolar 748 
to polar and even charged PTMs were installed using this method.151 The second took advantage 749 
of O-phosphoserine (Sep) insertion followed by dephosphorylation to obtain Dha. Alkyl iodides 750 
were then used to modify the Dha using the transmetalation from zinc to copper to form 751 
organocopper reagents and produce a radical alkyl species (300 equiv. alkyl iodide, 300 equiv. 752 
zinc powder, 100 equiv. organocopper, 30 min, r.t., pH 4.5, >80% conversion, Figure 8xiii). Using 753 
this method, all methylated forms of Lys PTMs were successfully formed.155 Beyond the insertion 754 
of PTMs into proteins, quite recently, Dha residues were harnessed as site-specific handles to 755 
access isotopic replacement techniques in proteins by performing a hydrogen–deuterium exchange 756 
at the a-carbon of the Dha residue, a nonexchangeable site in the protein backbone (first step after 757 
Dha formation in deuterated buffer: 15 equiv. Na3SPO3, 1 h, 37 ºC, pH 8.6; second step: PP1 758 
phosphatase, 1 h, 30 ºC, pH 8). Aside from some limitations that result from the formation of 759 
epimers at the deuterated site, the ability to isotopically label a protein site-specifically while 760 
avoiding complex biosynthetic methods allows for great potential in the monitoring and probing 761 
of modification mechanisms.156 Even with a lack of stereocontrol, the open-ended diversity for 762 
insertion at Dha sites has the potential to both unlock unknown protein functionality and redesign 763 
others.151  764 
While the toolkit of promising novel bioorthogonal reactions continues to expand, 765 
improvements push older bioorthogonal reactions closer to achieving a balance of reactivity and 766 
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stability for broader applicability. These improvements include: the discovery of a supramolecular-767 
mediated azide-alkyne reaction using cucurbit[6]uril that increases the solubility of reagents and 768 
facilitates reactions; the implementation of smaller, more stable 1,2,4-triazines in the place of 769 
tetrazines for IEDDA; the fusing of dioxolane to trans-cyclooctene (d-TCO) for increased stability 770 
and solubility while conserving high reaction rate (on the order of 105 M-1 s-1); an increase in 771 
selectivity for a diazo-coupling reaction by using 5-hydroxytryptophan instead of Tyr for a reaction 772 
with aromatic diazonium ions; and a method that takes advantage of prior knowledge on boronic 773 
acid tag capabilities by using the dynamic covalent character of boronic acid interactions with diols 774 
as a purification system before reacting the boronic acid with functionalized salicylhydroxamates 775 
to form a more stable product.133,136,137,157,158 Even with these improvements, strategies must 776 
continuously take into account the additional complications added when applications are meant 777 
for in vivo use (e.g. sodium periodate could not be used for oxidation in vivo, but enzymatic 778 
methods for oxidation may be able to replace it).145 An account highlighting the process of 779 
developing new bioorthogonal reagents and what is still lacking in the current toolbox of reactions 780 
and reactive pairs was recently published.159 At some point, the motivation for bioorthogonal 781 
research will have to change from attempts to find novel reactive pairs to optimizing those already 782 
discovered for efficient use.147 783 
 784 
[H1] Therapeutic and Diagnostic Applications 785 
There have been many reports of applications for protein conjugation, but we have limited 786 
discussion here to only the most recent reports that pertain to diagnostics and therapeutic 787 
intervention. Recently, there have been many discoveries of novel, controlled and targeted systems 788 
for radioimaging and the delivery of therapeutic protein conjugates.160–163 These systems rely on a 789 
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variety of targeting mechanisms: antibodies, nanobodies, or cyclic peptides, to gain this increased 790 
specificity and control. Both the targeting method and type of payload can be independently varied. 791 
In many cases, the stability and efficacy of the conjugate depends on the payload linker connecting 792 
the components.160,164,165 By combining creative targeting and payload choices, site-selective 793 
protein modification will continue to open doors to impactful and novel biological applications. 794 
 In the field of therapeutic conjugates, ADCs capture most of the attention.160 However, 795 
novel methods have been reported recently to either improve the ADC mechanism of action or to 796 
apply the idea of targeted delivery to alternate payloads (e.g. radioligands). All of these 797 
improvements require the assistance of selective protein conjugation methods.164,166–178 Strategies 798 
ranging from conventional to site-specific conjugation are still in use to drive these adjustments 799 
and optimizations. Conventional, selective Lys amidation has very recently reported as a method 800 
for conjugating thiol-based histone deacetylase (HDAC) inhibitors to cetuximab antibodies 801 
targeting EGFR (Table 2i). Less than 1% of the injected dosage of ADCs are expected to reach 802 
and be internalized by a target tumor, and as a result payloads for ADCs have been thought to 803 
require sub-nanomolar IC50 values. Meanwhile, HDAC inhibitors only have about a 0.07 µM IC50 804 
value. As the ADCs incorporating HDAC exhibited anti-tumor effects, this results suggests such 805 
highly toxic drugs are unnecessary and that off-site toxicity may be avoided by using lower 806 
potency drugs.166 Other payloads outside of the class of highly cytotoxic, anticancer drugs have 807 
also been successfully conjugated to antibodies (see Table 2 entries i-vi).168–172 Amazingly, the 808 
wide range of applications represented by these antibody-payload constructs is made possible by 809 
altering only the payload, conjugation chemistry, and linker, exemplifying how antibody 810 
conjugates can be viewed as a modular concept. 811 
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 Similarly, system variability is possible by moving away from the use of full-length 812 
antibodies and toward smaller antibody formats or even small molecule ligands as targeting 813 
mechanisms. Additionally, while some of these strategies were successful with conventional 814 
conjugation methods, a higher level of specificity is observed when more homogenous conjugates 815 
have been used with improvements in efficacy, pharmacokinetic properties, and diminished off-816 
site delivery.160 The instability and tissue penetration issues associated with the use of full-length 817 
antibodies for targeting has led to the use of alternative biomolecules with affinity-based targeting 818 
abilities (Table 2 entries vii-x).173–176 Rather than determining new functionality based on altering 819 
the payload identity, emphasizing the use of smaller targeting mechanisms has led to an increase 820 
in antibody-payload constructs efficacy. More specifically, such optimizations have uncovered 821 
methods for safer payload delivery, more effective payload distribution, and improved 822 
accessibility to medically relevant areas of the body that have not been explored by systems  823 
incorporatting full-length antibodies.173-176 824 
 In addition to methods targeting particular disease treatment, several recent studies have 825 
been aimed at illuminating the unknown mechanistic aspects of ADC approaches to drug delivery 826 
or to overcome foreseeable future issues related to antibody-targeting applications.164,167 As 827 
knowledge of the internalization and subsequent intracellular trafficking of ADCs remains quite 828 
limited, clever strategies are needed to enhance efficacy. One such strategy uses fluorescence 829 
resonance energy transfer (FRET) pairing to gain insight (Table 2xi). By incorporating a cleavable 830 
linker with one FRET fluorophore on the antibody side, attached by a maleimide-engineered Cys 831 
linkage, and one on the warhead side of the linker, when the linker is cleaved, both the antibody 832 
and payload can still be visualized and monitored. This method revealed the critical role that the 833 
cellular background has in internalization of the antibody.167 Beyond learning more information is 834 
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the anticipation of future problems in ADC performance, including the evolution of increased drug 835 
resistance. Therefore, a recently published report establishes THIO-SELENOMABs through the 836 
site-specific insertion of Cys and Sec to enable dual modification of the antibody (Table 2xii). 837 
Such dual modification would allow two different drugs with two different mechanisms of action 838 
to be delivered to the target cells, and, thus, potentially hinder the onslaught of resistance.164 839 
Similarly, a multidomain protein therapeutic has been designed by biotinylation of somatostatin 840 
(SST) and a Rho inhibitor (C3, Table 2xiii). The construct (SST3-Avi-C3) is made by the binding 841 
of three SSTs to avidin with one binding site left for the binding of C3. The C3 toxin can work in 842 
concert with doxorubicin to increase antitumor activity through the synergy of the two different 843 
mechanisms of attack.177 844 
 Rather than the targeted delivery of a payload, a recent perspective article discusses the 845 
advantages of using the antibody-antigen specific relationship for the creation of synthetic 846 
vaccines. Synthetic vaccines are generally composed of antigens conjugated to proteins (using a 847 
variety of techniques) which if proven viable would have a higher safety profile in comparison to 848 
whole organism-based vaccines. While synthetic vaccines still take advantage of the antibody–849 
antigen specific relationship, therapeutic applications involving protein conjugates also exist 850 
outside of antibody-related targeting.178 One such method involves the novel, N-terminal selective 851 
modification of cowpea chlorotic mottle virus (CCMV) capsid, a virus-like particle, using sortase 852 
A, allowing for higher encapsulation efficiencies of therapeutics for subsequent delivery.179 853 
Alternatively, protein–polymer conjugates, PEGylated and beyond, have been reviewed recently 854 
due to their therapeutic relevance.165 Aside from therapeutic and diagnostic applications, methods 855 
for the profiling and modulation of protein function are reliant upon the production of protein 856 
conjugates. For example, methods to explore histone PTMs using protein modification have 857 
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recently been reviewed. 100 While we have focused on therapeutic conjugates here, (with a 858 
particular emphasis on antibody-based targeting strategies), the conjugation methods presented in 859 
this review continue to be applied over many different fields of research, and the methods need to 860 
adapt and expand to meet ever-changing demands and needs. 861 
 Of note, the reaction conditions reported throughout this review reflect the information 862 
reported and available. For example, if certain methods do not have pH or conversion values in 863 
the list of conditions, it is due to the information not being clearly stated or reported. 864 
 865 
 866 
[H1] Summary and outlook 867 
While the methods in this review exemplify the major progress made in site-selective 868 
protein modification over the last five years, scientists have also been determining which direction 869 
the field needs to take to move forward. Whether incorporating new reactivities or refurbishing 870 
established chemistries, modification requirements are determined primarily by the complexity of 871 
the targeted biological system. For the modification of endogenous AA sidechains, N-/C-terminus 872 
and in-chain residue targeted methods need to be either tolerant of varying terminal AA types or 873 
use the unique tertiary structure of the target protein to improve specificity. These methods have 874 
the potential for high-yielding, one-step direct modification that avoids genetic engineering 875 
complexities. Both the identity of the target protein and the importance of product homogeneity to 876 
the application determine whether these methods may be used. On the other hand, genetic 877 
manipulation of the protein before modification allows for exquisite selectivity and versatility. 878 
While installed functionalities are limited based on natural translational tools and expression 879 
yields, high selectivity makes genetic manipulation the most desirable method to achieve 880 
homogeneity and has promoted the growth of bioorthogonal reaction types. Both endogenous AA 881 
 39 
sidechain modification and genetic manipulation have played prominent roles in biological 882 
applications, especially in therapeutic and diagnostic areas. However, such prominence has also 883 
revealed the many ways in which the field can still be improved or expanded. 884 
In general, an accurate prediction of future techniques can be determined by looking to 885 
new methods for peptide modification. Many protein modification methods are first proven using 886 
small molecules to exhibit functional group reactivity and before moving on to peptides and 887 
ultimately whole proteins. Peptide studies allow comparisons of varying AA sidechains before 888 
determining selectivity in longer AA sequences with complex tertiary structure. As such, methods 889 
that have been proven to show selectivity on peptides have strong potential for implementation in 890 
proteins. However, due to protein tertiary structure and large size, approximate reactivity with 891 
peptides does not necessarily reflect the protein interactions that will occur. A recently reported 892 
method addresses this by installing the reactive groups on well-known protein interaction faces.180 893 
Strategies similar to this, including computational design, calculations, and modeling, improve the 894 
efficiency and testing for new protein modification chemistries.181–183 Alternatively, it is important 895 
to acknowledge that older methods continue to develop and improve. This includes adjustments to 896 
allow for the installation of several similar or varying functionalities and for use in biological 897 
applications even outside of protein conjugation.184–186 While refining methodology can facilitate 898 
the discovery of new modification chemistries, the requirements that these new chemistries must 899 
fill are reliant on the purpose and demand of the application. 900 
Overall, these motivations and future directions allow insight into how best to assess and 901 
select modification methods and conditions to produce protein conjugates. By keeping in mind the 902 
intended application, whether targeted delivery or probing of a biological system, appropriate 903 
proteins should first be identified. Subsequently, the protein then determines if direct, native 904 
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modification techniques are possible or if a chemical handle should be installed genetically to 905 
promote a bioorthogonal reaction. Based on this determination, a more specific method (e.g. 906 
targeting N-/C-terminus, motif insertion, etc.) can be chosen based on how best to retain protein 907 
activity. If a bioorthogonal reaction is necessary, the application determines the stability, kinetics, 908 
and reactivity needed. By highlighting specific conditions, this review aims to guide scientists to 909 
helpful methods based on the specific limitations of their circumstances. Between modification 910 
methods already available and promising discoveries on the horizon, site-selective protein 911 
modification will lead to versatile biological applications more capable of providing critical 912 
information not only for therapeutic and diagnostic purposes, but also for profiling and modulating 913 
protein function to probe and manipulate novel complex systems.  914 
 915 
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Figure captions 1377 
 1378 
Figure 1 | Juxtaposition of classical and modern protein modification methods. On the left: 1379 
classical methods focused primarily on the modification of Cys and Lys sidechains. The 1380 
reactions most commonly focused on and depicted here include: thiol-exchange (i), alkylation of 1381 
a-halocarbonyl electrophiles (ii), maleimide Michael addition (iii), NHS-ester amidation (iv), 1382 
isothiocyanate or isocyanate addition (v), and reductive amination (vi).6,7 On the right: modern 1383 
methods focused on the improvement of selectivity, reaction efficiency, and generality of 1384 
application. The general modification classifications discussed in this review, as shown by 1385 
specific examples, are represented: native protein/endogenous AA sidechain modification, 1386 
engineered canonical AA insertion, engineered ncAA insertion, and motif/tag insertion.13–16 1387 
 1388 
Figure 2 | N-/C-terminal selective protein modification. Above: C-terminal modification 1389 
based on a decarboxylative strategy facilitated by a photocatalyst (i).16 Below: N-terminal 1390 
modification techniques based on oxidative (ii), direct (iii), reductive (iv), or enzymatic type 1391 
reactions (v).24–26,29 To mention a few more specific points on each reaction: (i) While not tested 1392 
with glycine, phenylalanine, or proline as C-terminal residues, desired products were observed 1393 
for all other AAs with lower yields for histidine (His), tyrosine (Tyr), and lysine (Lys) terminal 1394 
AAs.16 (ii) Best with proline in the terminal position (only residue allowing for high yields at the 1395 
protein level) and not performed with cysteine in the terminal position unless only cysteine in 1396 
protein sequence as method modifies cysteine residues regardless of terminal position.26 (iii) 1397 
This method has been exhibited with all AAs in terminal positions but cannot be performed on 1398 
proteins with proline in the second position.25 (iv) With the exception of cysteine as the terminal 1399 
residue due to thiazolidine side products, all types of terminal AAs achieve high yields.24 (v) 1400 
Butelase 1 can interact with a variety of terminal AA types aside from proline and prefers the 1401 
second position to be either, isoleucine, valine, leucine, or cysteine. Most of the terminal AA 1402 
type compatibility types were performed on peptide platforms.29 1403 
 1404 
Figure 3 | In-chain endogenous sidechain modification. Methods for endogenous sidechain 1405 
modification of in-chain residues. The recent discoveries and reports of successful strategies 1406 
have followed three different trends: modification based on selection of conditions and reagents 1407 
to target the most reactive instance of a repeated sidechain, site-selective modification based on 1408 
the direction of metals and ligands to native binding sites, and modification via disulfide 1409 
rebridging. Each trend has several valuable examples that have been established in the last five 1410 
years and are represented. Reagent- or condition-based targeting of the most reactive instance of 1411 
an AA: selective trifluoromethylation of tryptophan residues (i), sulfonyl acrylate modification 1412 
of most reactive lysine (ii), a three-component reaction for the modification of a single lysine 1413 
(iii).12,33,34 Ligand- or metal-binding site directed methods: Cys arylation based on proximity to 1414 
Asp-regulated binding site (iv), selective modification of Tyr residues proximal to the SH3 1415 
binding domain (v), diazotransfer to lysines proximal to ligand site (vi), metallopeptide targeted 1416 
Asp modification in antibodies using Fc-binding peptides (vii).19,32,37,39 Disulfide rebridging: by 1417 
oxetanes (viii), by water-soluble allyl sulfones (ix), by dibromide-based moieties (x), and by 1418 
thiol-yne coupling (xi).43,45–50 The colored highlights represent different reactive handles or 1419 
functionalities added to the protein by the conjugation reactions. 1420 
 1421 
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Figure 4 | Modification methods for engineered Cys residues. Out of all of the canonical AAs 1422 
for the installation of chemical handles in proteins, Cys residues have the broadest reactivity 1423 
profile as represented by these examples. The methods have been separated into three classifying 1424 
groups: metal-free, metal-assisted, and reversible type reactions. As the eventual application for 1425 
the bioconjugate determines the type of chemistry linking the added functionality and the 1426 
protein, these three categories all represent different mechanistic strategies that would allow 1427 
these methods to be useful under various circumstances (e.g. cleavable linkers for ADCs to 1428 
prevent reliance on release of the attached drug by native cell processes). Metal-free methods: 1429 
addition of alkyl bromide electrophilic handles via an isobutylene and oxetane type chemical 1430 
handle (i and ii), amine functionalization followed by addition of CBTF (iii), S-arylation by 1431 
fluorobenzene derivatives (iv), addition of carbonylacrylic reagents (v), allenamide addition (vi), 1432 
cyclopropenyl ketone addition (vii), chlorotetrazine addition (viii), and 2-azidoacrylate addition 1433 
(ix).15,59–61,63–67 Metal-assisted methods: S-arylation by way of Au(III) (x) or Pd(II) catalyst 1434 
(xi).70,72 Reversible methods: addition of 5MP derivatives (xii), addition of 4-acetoxy 1435 
cyclopentenone (xiii), 2-FPBA addition at the N-terminus (xiv), and the addition of NQMPs 1436 
(xv).73–76 1437 
 1438 
Figure 5 | Insertion of canonical amino acids aside from Cys. Site-selective protein 1439 
modification based on the genetic insertion of canonical AAs aside from Cys. Forming unique 1440 
reactive handles when inserted due to low abundance or being unlikely to be expressed 1441 
endogenously in a solvent accessible position, these inserted AAs (Trp, Tyr, His, and Met) allow 1442 
modifications that will lead to products with higher levels of homogeneity. Trp modification: a 1443 
metal-assisted reaction with TIPS-EBX to install a protected alkyne reactive handle 1444 
regioselectively at the C2 position on the indole rings of installed Trp residues (i);83 using an 1445 
organoradical-driven mechanism, keto-ABNO derivatives add to the indole ring of Trp residues 1446 
with elevated conversion in acidic environments (ii);79 in the presence of H2O2 and hemin, luminol 1447 
derivatives are added to Tyr ortho positions (iii);84 Rh(III)-mediated reaction for the addition of 1448 
arene complexes to Tyr ortho positions (iv).86 Pt(II)- and Ru(II)-driven selective complexation 1449 
with His residues (v and vi);81,82 and a metal-free, redox-based reaction targeting Met residues with 1450 
oxaziridine derivatives (vii).78 1451 
 1452 
Figure 6 | Insertion of ncAAs. The most common method and novel chemistries made available 1453 
by ncAA insertion over the last five years: a) Depiction of the groundbreaking use of orthogonal 1454 
aminoacyl tRNA synthetase/tRNA pairs for the insertion of ncAAs.90–93 1 - Binding of tRNA and 1455 
ncAA to aminoacyl tRNA synthetase (aaRS). 2 - Attachment of ncAA to tRNA by aaRS. 3 – 1456 
Recognition of the amber codon by the ncAA-equipped tRNA. 4 – Incorporation of ncAA into 1457 
the protein sequence by a native ribosome. b) examples of ncAAs that have been synthesized and 1458 
inserted into proteins for the first time over the last five years. The colored highlights on the 1459 
ncAA examples represent different chemical handles or functionalities added to the protein when 1460 
the respective ncAAs are inserted. The red-highlight for HibK is to signify the PTM that this 1461 
ncAA directly inserts.101 Orange highlights represent protection groups that must be removed to 1462 
reveal a phosphorylation PTM or an allysine residue that can be hydrolyzed to an aldehyde 1463 
functionality (pTyr and AcdK respectively).102,103 Blue highlights shows the photo-reactive 1464 
moieties that allow for further functionalization of the protein or crosslinking.13,107–109 While the 1465 
green highlights different electrophilic handles incorporated by these ncAAs, the purple highlight 1466 
signifies a nucleophilic site for subsequent reactions.104–106,108,109 1467 
 57 
 1468 
Figure 7 | Motif and enzymatic tag insertion. Rather than the insertion of single residues and 1469 
reliance only on the chemistry of the added functional group to drive selectivity, the insertion of 1470 
tags allows for manipulation of the microenvironment around specific AAs. Such manipulation 1471 
can lead to elevated reactivity of the targeted AA or to the enzymatic recognition of the inserted 1472 
tag. In either case, the site-specific modification of the targeted residue within the motif or tag 1473 
occurs. Ideal motif insertion methods allow for site-specific modification at either in-chain or 1474 
terminal sites as well as cause minimal disruption of the protein structure, even with multiple 1475 
instances of the tag inserted. Methods discussed here: fluorette fusion for fluorophore 1476 
functionalization (i), modification mediated by TTL (ii), modification mediated by trypsiligase 1477 
(iii), DBCO tag for Cys modification (iv), tag for CBT modification of Cys (v), π-clamp for Cys 1478 
modification (vi), Lys activation by HSAdI (vii), noncanonical function of sortase A allows for 1479 
Lys-specific modification of inserted pilin domain (viii).14,114–116,118–122 1480 
 1481 
Figure 8 | Downstream functionalization methods. Clean and efficient modification of unique, 1482 
bioorthogonal chemical handles. A general scheme of the concept of “click chemistry” is included 1483 
at the top of the diagram.131–133 The methods highlighted here fall under four classifications: 1484 
alkyne-based reactions, aldehyde-based reactions, methods aside from alkyne- and aldehyde-based 1485 
reactions, and Dha functionalization. Alkyne-based reactions: SPOCQ cycloaddition (i), phenyl 1486 
sydnones [3+2] cycloaddition with BCN (ii), Glaser-Hay coupling (iii), Ru(II)-catalyzed alkyne 1487 
hydrosilylation (iv).135,138–140 Aldehyde-based reactions: trapped Knoevenagel-type condensation 1488 
(v), tandem Knoevenagel-type condensation (vi), aldol reaction with 2,4-thiazolidinediones and 1489 
an N-terminal aldehyde (vii), OPAL with an inserted aldehyde functionality (viii).142–145 Methods 1490 
aside from alkyne- and aldehyde-based strategies: phospha-Michael addition (ix), QC ligation (x), 1491 
triarylphosphine-mediated addition to cyclopropenone (xi).146–148 Methods for Dha modification: 1492 
aza-Michael addition to Dha (xii), radical-based reactions for the formation of C–C bonds with 1493 
Dha (xiii).151,153–155 1494 
 1495 
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Table 1. Overview of modification method components and key features  1498 
 1499 
Approach Possible reagents for modification or insertion Key features 
Direct modification 
of native proteins 
N-/C-terminus 
modification 
Michael acceptors (visible-
light-mediated SET 
method); o-aminophenols; 
2-PCA; aldehydes; 
thiodepsipeptides 
(mediated by butelase 1) 
Advantages:  
-General method for site-
specific modification of single 
chain native proteins due to 
distinct termini 
microenvironments 
-Termini tend to be solvent 
accessible 
-No genetic engineering 
needed 
 
Limitations:  
-Termini need to be available 
for modification (i.e. not vital 
for protein function and no 
PTMs) 
-Sometimes dependent on 
identity of terminal AA 
residue 
In-chain residue 
modification 
Reactive-residue targeting: 
Sodium 
trifluoromethanesulfinate 
(Trp modification); 
sulfonyl acrylates (Lys 
modification); 
multicomponent reaction 
with aldehydes, alkynes, 
and copper(I) iodide (Lys 
modification) 
 
Proximity-induced: 
aryl halides for Cys 
arylation based on Pd(II) 
binding site; aryldiazonium 
addition to Tyr guided by 
SH3 domain-binding 
peptides; Cu(II) catalyzed 
diazotransfer to proximal 
Lys at binding sites; 
metallopeptide addition 
based on SH3 and Fc 
Advantages: 
-With careful reaction/reagent 
selection, can rely on distinct 
microenvironment for 
targeting a single residue 
-Possible to use 
substoichiometric amount of 
targeting component when 
using binding site for 
proximity-induced 
modifications 
-Disulfide rebridging allows 
control over modification site  
-No genetic engineering 
needed 
 
Limitations: 
-Necessary to either have a 
distinct microenvironment to 
enhance reactivity of a 
specific residue or have a 
native metal- or ligand-
 59 
domain-binding peptides; 
antibody heavy chain 
junction-binding protein 
targeted modification of 
lysine; LDM method for 
modification of His  
 
Disulfide rebridging:  
oxetanes; allyl sulfones; 
DVP; dibromo-PBD 
derivatives; alkynes for 
photomediated thiol-yne 
reactions 
binding site as well as a 
proximal reactive residue 
-Smaller size needed for 
disulfide rebridging reagents 
-Little control over choice of 
modification site  
Protein 
modification via 
genetic 
manipulation 
Canonical AA 
insertion: 
cysteine 
Isobutylene and oxetane 
bromo-derivatives; CBTF; 
fluorobenzenes; 
carbonylacrylic 
derivatives; allenamides; 
cyclopropenyl ketones; 
dichlorotetrazines; 2-
azidoacrylate reagents; 
Au(III) and Pd(II) 
complexes for S-arylation; 
5MPs; 4-acetoxy 
cyclopentenones; 2-FPBA; 
NQMPs 
Advantages: 
-Broad reactivity profile of 
cysteine  
-Numerous previously 
determined methods for 
modification 
-Low abundance of Cys 
allowing for higher 
modification site selectivity 
-Easier to express mutations 
for canonical AAs than 
ncAAs 
 
Limitations: 
-Possible disulfide disruption 
or shuffling with reduction 
step needed to free Cys thiol 
for modification 
-Cannot be used in proteins 
where reactive Cys residue 
plays a critical role in protein 
activity 
Canonical AA 
insertion: other 
low-abundance 
canonical AAs 
TIPS-EBX (metal-
mediated Trp 
modification); keto-ABNO 
(organoradical Trp 
modification); N-
methylated luminol 
derivatives (hemin-
catalyzed method for Tyr 
modification); arene 
complexes (modification 
method for Tyr using 
Advantages: 
-Residues focused on here 
(Trp, Tyr, Met, His, and Sec) 
have higher chances to form 
unique chemical handles 
based on low abundance and 
expected positioning within 
the protein structure  
-Easier to express mutations 
for canonical AAs than 
ncAAs 
 60 
Rh(III)); Pt(II) and Ru(II) 
complexes (His 
modification); oxaziridine 
reagents (Met 
modification); hypervalent 
iodonium salts (Met 
modification); electron-
rich arenes (Sec 
modification) 
 
Limitations: 
-More difficult to use 
biologically compatible 
conditions to modify these 
less reactive side chains and 
often observe lower 
conversions 
-Difficult to achieve high 
selectivity due to the need for 
more reactive modifying 
reagents or conditions 
ncAA insertion 
HibK; pTyr; AcdK; photo-
lysine; FPheK; pNCSF; 
ThioD; ACTKs; 
AmAzLys; PSCaas 
Advantages: 
-The inserted ncAA chemical 
handle is unique and can be 
matched with a reactive pair 
for site-specific modification 
-Different methods for 
incorporating ncAAs have 
been discovered 
-Allows clean and efficient 
reactions that can be done in 
cells 
-Can mimic precise placement 
of PTMs 
 
Limitations: 
-Multiple step syntheses for 
the production of ncAAs 
-Complexities inherent in 
expression technologies and 
capabilities often leading to 
low levels of expression of the 
mutated protein and limited 
insertion of which functional 
groups able to be inserted 
Motif insertion 
and enzymatic 
methods 
TexasRed fluorette for the 
covalent attachment of 
TexasRed to Cys; TTL for 
attachment of Tyr 
derivatives to Tub-tag; 
trypsiligase for the 
attachment of OGp to 
YRH tag; DBCO-tag, 
CBT-tag, π-clamp (for 
perfluoroaromatic 
Advantages: 
-Expression of canonical AA 
mutations more successful 
than ncAA 
-Target residue activated by 
microenvironment 
manipulation or enzymatic 
recognition leading to site-
specific reactions 
 
 61 
reagents), and Dis-tag for 
Cys activation; 
cyclohexene sulfonamide 
and LPXTG substrates for 
the modification of Lys 
mediated by inserted 
HSAdI and pilin domains 
respectively; His2-tag for 
modification of two His 
residues proximal to each 
other 
Limitations: 
-Tag size cannot be too large 
and positions for insertion are 
limited based on retaining 
protein function  
-For enzymatic modification, 
enzymes need to be readily 
available and affordable 
 1500 
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Table 2. Therapeutic and Diagnostic Applications of Protein Conjugates 1502 
 1503 
Targeting 
component 
Added 
functionality 
Conjugation 
method Specified conditions 
Relevance in 
research field 
(i) 
cetuximab 
(targeting 
EGFR 
antigen)166 
HDAC 
inhibitors  
(IC50 = 0.07 
µM) 
conventional 
(Lys selective 
amidation) 
Step 1:  
1 equiv. payload, 1.75 equiv. 
N,N’-dicyclohexylcarbodiimide, 
1.5 equiv. 
N-hydroxysuccinimide, 16 h, 
r.t., DMF 
 
Step 2: 
20 equiv. activated payload, 1 h, 
r.t., pH 7.4 
Therapeutic delivery 
of medium-cytotoxic 
drugs for the 
treatment of 
neurological 
disorders, 
inflammation, viral 
and protozoal 
infections, 
cardiovascular 
disorders, and cancer 
(ii) 
anti-CXCR4 
(targeting 
T-lymphocyte 
antigen)168 
dasatinib  
(Lck inhibitor, 
IC50 < 1 nM) 
Step 1: 
conventional 
(Lys selective 
amidation)  
 
Step 2: 
aldehyde-based 
click reaction 
(oxime formation) 
Step 1:  
30 equiv. N-succinimidyl-4- 
formylbenzamine, 3 h, r.t., pH 
7.4 
 
Step 2:  
30 equiv. dasatinib, 24 h, 37 ºC, 
pH 5-7, >95% conversion 
Suppression of 
T-cell activation and 
cytokine expression 
for the treatment of 
T-cell mediated 
immune disorders 
(iii) 
anti-WTA 
(targeting 
wall-teichoic 
acids of S. 
aureus)169 
rifalogue 
antibiotic  
(kills both 
replicating and 
non-replicating 
intracellular 
bacteria) 
canonical AA 
insertion (Cys 
selective 
maleimide-based 
conjugation) 
3 equiv. payload, 1 h Elimination of 
intracellular S. 
aureus (a major 
contributor to 
invasive infections 
and is resistant to 
regular antibiotic 
treatments), and the 
method holds 
potential for the 
treatment of other 
intracellular 
pathogens 
(iv) 
mouse IgG1-
Apoliprotein 
A1a  
(targeted by a 
secondary 
antibody - goat 
anti-mouse 
IgG H+L)170 
nucleotide 
(azide-
functionalized)  
Step 1:  
conventional (Lys 
selective 
amidation)  
 
Step 2:  
alkyne-based click 
chemistry 
(SPAAC) 
Step 1:  
5 equiv. DBCO reagent, 2 h, r.t., 
pH 7.4 
 
Step 2:  
10 equiv. nucleotide, 16 h, 4 ºC, 
pH 7.4 
A colorimetric read-
out of nucleotide 
incorporation by 
using enzyme-linked 
immunosorbent 
assays based on the 
targeting of an 
antibody conjugate 
incorporated into the 
DNA 
(v) 
trastuzumab 
(HER2 
targeting 
antibody)171 
thiol-reactive 
bifunctional 
chelators to 
allow labeling 
by 89Zr and 
177Lu 
canonical AA 
insertion (Cys 
selective reaction 
with 
phenyloxadiazolyl 
methylsulfone 
(PODS) reagents) 
10 equiv. PODS reagent, 10 
equiv. TCEP, 2 h, r.t., pH 7.4 
Improved stability of 
radiolabeling of 
bioconjugates for 
PET with lower 
background signals 
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(vi) 
trastuzumab 
(HER2 
targeting 
antibody)172 
KSPis 
(pyrrole 
subclass)  
Step 1: 
conventional (Cys 
modification by 
partial reduction 
of disulfide bonds 
with maleimide 
reagent) 
 
Step 2: 
promotion of 
thiosuccinimde 
ring hydrolysis 
and stabilization 
of ADC product 
Step 1: 
1 h, r.t. 
 
Step 2: 
overnight, r.t., pH 8 
Introduces new 
antitumor payload 
for the creation of 
ADCs. KSPis follow 
an alternative 
mechanism to those 
of usual payload 
classes (DNA 
intercalators and 
tubulin inhibitors). 
KSPis prevent 
centrosome 
separation during the 
cell cycle. 
(vii) 
cyclic-RGD 
peptides 
(targeting avb3 
integrin 
receptors in 
tumor 
vasculature)173 
adeno-
associated 
virus capsid 
(functionalized 
via azido-Lys 
ncAA) 
Step 1: 
ncAA insertion 
(azido-Lys) 
 
Step 2: 
alkyne-based click 
chemistry 
(SPAAC) 
2 h, r.t. Creates targeted 
delivery for safer 
gene therapy for 
anticancer treatment 
by redirecting 
binding target of the 
adeno-associated 
virus capsid 
(viii) 
single-chain 
antibody 
fragments 
(three different 
endothelial-
targeting 
fragments)174 
azide-
containing 
peptide and 
antioxidant 
enzyme 
 
Step 1: 
enzymatic tag 
insertion  
(sortase A 
mediated 
conjugation) 
 
Step 2: 
alkyne-based click 
chemistry 
(SPAAC) 
Step 1:  
1 equiv. scFv, 1 equiv. sortase 
A, 5 equiv. azide-containing 
peptide, 16 h, r.t., pH 7.5, 
conversion >95% 
 
Step 2:  
4 equiv. scFv, 1 equiv. 
DBCO-functionalized catalase, 
overnight, r.t. 
Targeted-therapeutic 
for vascular 
endothelial cells as 
they act as sites of 
interest in 
thrombotic, 
ischemic, and 
inflammatory 
conditions and could 
furthermore 
modulate passage of 
macromolecules or 
drug carriers from 
vasculature areas to 
target organs 
(ix) 
nanobody 
(anti-EGFR)175 
upconversion 
nanoparticles 
loaded with 
the drug 
doxorubicin 
enzymatic tag 
insertion 
(C-terminal 
conjugation with 
microbial 
transglutaminase) 
1 h, r.t. Targeted delivery of 
anticancer drugs 
demonstrated using 
PEGylated 
nanobodies tethered 
to human serum 
albumin coated 
upconversion 
nanoparticles loaded 
with doxorubicin 
(x) 
affibodies 
(anti-EGFR)176 
Benzophenone 
for photo-
cross-linking 
to EGFR 
receptor 
Step 1: 
canonical AA 
insertion 
(engineered Cys 
modification by 
maleimide 
moiety) 
 
Step 2: 
Step 1: 
20 equiv. 4N-maleimido-
benzophenone, overnight, r.t., 
pH 7.4 
 
Step 2: 
127 equiv. EGFR extracellular 
domain, near UV (365 nm), 1 h 
Smaller size and 
lesser affinity for 
EGFR allows for an 
affibody-targeted 
system to have 
deeper penetration 
into a solid tumor 
environment. 
Crosslinking the 
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once modified 
affibodies 
throughout tumor 
environment, 
upconversion 
nanoparticles used 
in tandem to 
deliver local 
irradiation for 
crosslinking 
affibody to the 
EGFR receptor 
allows for the 
distribution of the 
affibody construct to 
be retained for 
longer in the tumor 
environment. 
(xi) 
anti-HER2 and 
anti-TenB2  
(HER2 and 
tomoregulin 
targeting 
antibodies)167 
maytansinoid 
DM1 cytotoxic 
drug linked to 
antibodies via 
a linker with 
two 
fluorophores 
present on 
either side of a 
cleavage site 
canonical AA 
insertion 
(engineered Cys 
modification by 
maleimide 
moiety) 
no specifics reported Due to having a 
cleavable linker with 
FRET fluorophores 
on either side, the 
antibody and 
payload can be 
tracked even after 
the linker has been 
cleaved and provide 
more information on 
internalization and 
intracellular 
trafficking.  
(xii) 
trastuzumab 
(HER2 
targeting 
antibody)164 
biotin and 
fluorophore 
functionalities  
canonical AA 
insertion 
(engineered Cys 
selective reaction 
and engineered 
Sec selective 
reaction) 
Step 1 (Sec-modification):  
derivatives (iodoacetamide or 
methylsulfone based), 25 equiv. 
DTT, 30-60 min, r.t., pH 5.2, 
2.5 equiv. biotin  
 
Step 2 (Cys modification):  
5 equiv. 
methylsulfone-functionalized 
fluorophore, 1 h, r.t., pH 7.4 
Possible strategy to 
overcome the 
developing 
resistance seen to 
current ADCs, site-
specific conjugation 
of two different 
drugs 
(xiii) 
SST 
(targeting 
SST-2 
receptors on 
cancer cells 
that have been 
biotinylated)177 
C3 (a Rho 
inhibitor that 
has been 
biotinylated) 
For SST: 
in-chain residue 
modification 
(disulfide 
rebridging) 
 
For C3: 
canonical AA 
insertion 
(engineered Cys 
to be modified by 
maleimide) 
For SST: 
pH 7.8 
 
For C3: 
30 equiv. biotinylated reagent, 
3 h, r.t., pH 7.4 
An alternative 
strategy for 
overcoming cancer 
cell resistance to 
mechanisms of 
certain drugs. 
aIn this case, the antibody involved in the nucleotide conjugate is the target of a secondary antibody that allows the 1504 
colorimetric assay to visualize the nucleotide-antibody conjugate incorporation into DNA. 1505 
  1506 
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Glossary: 1507 
 1508 
Site-selective: 1509 
Modification methods that target a certain residue over other types of amino acids. 1510 
 1511 
Site-specific: 1512 
Modification methods that target a single occurrence of a particular type of amino acid. 1513 
 1514 
Endogenous residues: 1515 
Amino acid residues that are present in the native sequence of a protein based on the unaltered 1516 
genes of the host organism. 1517 
 1518 
Canonical amino acids: 1519 
The standard 20 amino acid types encoded and inserted naturally by the genetic code and by 1520 
native protein biosynthesis systems.  1521 
 1522 
Protein microenvironment: 1523 
The manipulation of amino acid sidechain properties (e.g. steric or electric characteristics) and 1524 
reactivity based upon the identity of surrounding amino acids in the protein sequence.  1525 
 1526 
Noncanonical amino acids: 1527 
Amino acids that are most often synthesized and non-proteinogenic (with the exception of 1528 
selenocysteine and pyrrolysine) and can either be inserted residue- or site-specifically into 1529 
protein sequences. 1530 
 1531 
Heterogenous products: 1532 
Protein conjugates that have different constitutions based on the conjugation method binding 1533 
differing amino acid types or various occurrences of the same amino acid type.  1534 
 1535 
Human insulin:  1536 
A protein that is made up of two separate chains of amino acids labeled as A and B, bound 1537 
together by two disulfide bridges. 1538 
 1539 
Post translational modifications: 1540 
Post-translational, covalent protein modifications that have critical roles in cell signaling and 1541 
control of protein activation or function. 1542 
 1543 
SH3 domain proteins: 1544 
Proteins that contain SH3 domains for the regulation of cytoplasmic signaling pathways. 1545 
 1546 
Bioorthogonal reactions: 1547 
Chemical reactions that can be executed in the complex environment of living systems (i.e. in the 1548 
presence of many nucleophiles, reductants, etc.) without altering or affecting native processes.  1549 
 1550 
 1551 
 1552 
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Antibodies: 1553 
Proteins that are composed of two main regions: Fc regions (constant regions for the support and 1554 
stability of the antibody) and Fab regions (variable regions of the antibody that must be 1555 
preserved in order to retain affinity and specificity for a corresponding antigen). 1556 
 1557 
Click chemistry: 1558 
Chemical reactions that can be defined based on high reaction and conversion rate, green solvent 1559 
systems, low byproduct levels, and broad functional group applicability. 1560 
 1561 
Conjugate payload: 1562 
The chemical linker and added functionality (e.g. fluorophore, cytotoxic drug, etc.) in a protein 1563 
conjugate. 1564 
 1565 
Disulfide rebridging: 1566 
Process by which two cysteine residues, revealed by disulfide reduction, reform the disrupted 1567 
disulfide either through the construction of a mixed disulfide or through the introduction of a 1568 
synthetic stapling molecule to connect the two residues 1569 
 1570 
Orthogonal tRNA/RS pairs: 1571 
These orthogonal pairs can use native protein biosynthesis machinery for the site-specific 1572 
insertion of noncanonical amino acids and require that no native RS be able to aminoacylate the 1573 
incorporated tRNA and no native tRNA be modified by the incorporated RS.  1574 
 1575 
Fusion protein: 1576 
Proteins that are produced by combining parts from different proteins or proteins with smaller 1577 
amino acid sequences/tags to create one expressed entity. 1578 
 1579 
Upconversion nanoparticles: 1580 
Nanoscale particles that allow for photon upconversion (the absorption of two lower-energy 1581 
photons to create one higher-energy, emitted photon) for imaging and sensors in deep tissue 1582 
environments.  1583 
 1584 
 1585 
